<div class="Article" id="mathjax-container" role="main"><div class="accessbar-sticky"><div id="screen-reader-main-content"></div><div role="region" aria-label="Download options and search"><div class="accessbar"><div class="accessbar-label"></div><ul aria-label="PDF Options"><li class="ViewPDF"><a class="link-button accessbar-utility-component accessbar-utility-link link-button-primary link-button-icon-left" target="_blank" aria-label="View PDF. Opens in a new window." href="/science/article/pii/S000349672504289X/pdfft?md5=a42d0444104fee3add6d1851c8fc5021&amp;pid=1-s2.0-S000349672504289X-main.pdf" rel="nofollow"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="link-button-text-container"><span class="link-button-text"><span>View&nbsp;<strong>PDF</strong></span></span></span></a></li><li class="DownloadFullIssue"><button class="button-link accessbar-utility-component button-link-primary" type="button" aria-label="Download full issue"><span class="button-link-text-container"><span class="button-link-text"><span>Download full issue</span></span></span></button></li></ul><form class="QuickSearch" action="/search#submit" method="get" aria-label="form"><div class="text-input"><div class="text-input-container text-input-container-no-label"><label class="text-input-label u-hide-visually" for="article-quick-search">Search ScienceDirect</label><input type="search" id="article-quick-search" name="qs" class="text-input-field" aria-describedby="article-quick-search-description-message " aria-invalid="false" aria-label="Search ScienceDirect" placeholder="Search ScienceDirect" value=""></div><div class="text-input-message-container"><div class="text-input-validation-error" aria-live="polite"></div><div id="article-quick-search-description-message"></div></div></div><button type="submit" class="button u-margin-xs-left button-primary small button-icon-only" aria-disabled="false" aria-label="Submit search"><svg focusable="false" viewBox="0 0 100 128" height="20" class="icon icon-search"><path d="M19.22 76.91c-5.84-5.84-9.05-13.6-9.05-21.85s3.21-16.01 9.05-21.85c5.84-5.83 13.59-9.05 21.85-9.05 8.25 0 16.01 3.22 21.84 9.05 5.84 5.84 9.05 13.6 9.05 21.85s-3.21 16.01-9.05 21.85c-5.83 5.83-13.59 9.05-21.84 9.05-8.26 0-16.01-3.22-21.85-9.05zm80.33 29.6L73.23 80.19c5.61-7.15 8.68-15.9 8.68-25.13 0-10.91-4.25-21.17-11.96-28.88-7.72-7.71-17.97-11.96-28.88-11.96S19.9 18.47 12.19 26.18C4.47 33.89.22 44.15.22 55.06s4.25 21.17 11.97 28.88C19.9 91.65 30.16 95.9 41.07 95.9c9.23 0 17.98-3.07 25.13-8.68l26.32 26.32 7.03-7.03"></path></svg></button><input type="hidden" name="origin" value="article"><input type="hidden" name="zone" value="qSearch"></form></div></div></div><div class="article-wrapper grid row"><div role="navigation" class="u-display-block-from-lg col-lg-6 u-padding-s-top sticky-table-of-contents" aria-label="Table of contents"><div class="TableOfContents" lang="en"><div id="reading-assistant-container"></div><div class="Outline" id="toc-outline"><h2 class="u-h4">Outline</h2><ol class="u-padding-xs-bottom"><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#abs0001" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="ABSTRACT"><span class="anchor-text-container"><span class="anchor-text">ABSTRACT</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0003" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="INTRODUCTION"><span class="anchor-text-container"><span class="anchor-text">INTRODUCTION</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0004" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="METHODS"><span class="anchor-text-container"><span class="anchor-text">METHODS</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0013" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="RESULTS"><span class="anchor-text-container"><span class="anchor-text">RESULTS</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0017" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="DISCUSSION"><span class="anchor-text-container"><span class="anchor-text">DISCUSSION</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#coi0001" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Competing interests"><span class="anchor-text-container"><span class="anchor-text">Competing interests</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0018" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Acknowledgements"><span class="anchor-text-container"><span class="anchor-text">Acknowledgements</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0019" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Contributors"><span class="anchor-text-container"><span class="anchor-text">Contributors</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0020" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Funding"><span class="anchor-text-container"><span class="anchor-text">Funding</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0021" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title=""><span class="anchor-text-container"><span class="anchor-text"><strong>Patient consent for publication</strong></span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0022" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Ethics approval"><span class="anchor-text-container"><span class="anchor-text">Ethics approval</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0023" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Provenance and peer review"><span class="anchor-text-container"><span class="anchor-text">Provenance and peer review</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#sec0025" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="Appendix. Supplementary materials"><span class="anchor-text-container"><span class="anchor-text">Appendix. Supplementary materials</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary" href="#cebibl1" data-aa-button="sd:product:journal:article:type=anchor:name=outlinelink" title="REFERENCES"><span class="anchor-text-container"><span class="anchor-text">REFERENCES</span></span></a></li></ol><button class="button-link u-margin-xs-top u-margin-s-bottom button-link-primary button-link-icon-right" type="button" aria-expanded="false" data-aa-button="sd:product:journal:article:type=menu:name=show-full-outline"><span class="button-link-text-container"><span class="button-link-text">Show full outline</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button><div class="PageDivider"></div></div><div class="Figures" id="toc-figures"><h2 class="u-h4">Figures (3)</h2><ol class="u-margin-s-bottom"><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0001" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 1. Enrolment and randomisation of patients" class="u-display-block" height="164px" src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr1.sml" width="218px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0002" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 2. Response to treatment at 28 and 52 weeks by intention-to-treat analysis" class="u-display-block" height="152px" src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr2.sml" width="219px"></a></li><li><a class="anchor u-display-block anchor-primary anchor-icon-only anchor-with-icon" href="#fig0003" data-aa-button="sd:product:journal:article:type=anchor:name=figure"><img alt="Figure 3. Changes in levels of (A) white blood cell counts (WBC), (B) lymphocyte counts…" class="u-display-block" height="164px" src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr3.sml" width="197px"></a></li></ol><div class="PageDivider"></div></div><div class="Tables" id="toc-tables"><h2 class="u-h4">Tables (3)</h2><ol class="u-padding-s-bottom"><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#tbl0001" data-aa-button="sd:product:journal:article:type=anchor:name=table" title="Characteristics of the study patients at entry into the trial"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-table"><path d="M54 68h32v32H54V68zm-42 0h32v32H12V68zm0-42h32v32H12V26zm42 0h32v32H54V26zM2 110h94V16H2v94z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Table 1</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#tbl0002" data-aa-button="sd:product:journal:article:type=anchor:name=table" title="Response to treatment at 28 and 52 weeks by intention-to-treat and per-protocol analysis"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-table"><path d="M54 68h32v32H54V68zm-42 0h32v32H12V68zm0-42h32v32H12V26zm42 0h32v32H54V26zM2 110h94V16H2v94z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Table 2</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#tbl0003" data-aa-button="sd:product:journal:article:type=anchor:name=table" title="Adverse events during the trial"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-table"><path d="M54 68h32v32H54V68zm-42 0h32v32H12V68zm0-42h32v32H12V26zm42 0h32v32H54V26zM2 110h94V16H2v94z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Table 3</span></span></a></li></ol><div class="PageDivider"></div></div><div class="Extras" id="toc-extras"><h2 class="u-h4">Extras (2)</h2><ol class="u-padding-s-bottom"><li><span class="download-all-supplemental-data"><span class="in-toc"><iframe title="download_all" name="download_all" class="u-hide"></iframe><form method="post" action="/sdfe/pdf/download/S000349672504289X/attachments" target="download_all"><input name="eids" type="hidden" value="1-s2.0-S000349672504289X-mmc1.docx"><input name="eids" type="hidden" value="1-s2.0-S000349672504289X-mmc2.docx"><button class="button-link download-all-button u-font-sans u-margin-xs-bottom button-link-primary button-link-icon-left" type="submit"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-download"><path d="M77.38 56.18l-6.6-7.06L54 66.36V26H44v40.34L26.28 49.1l-7.3 7.08 29.2 29.32 29.2-29.32M88 74v20H10V74H0v30h98V74H88"></path></svg><span class="button-link-text-container"><span class="button-link-text"><span class="download-all-title">Download all </span></span></span></button></form></span></span></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0001" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Document"><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-text-document"><path d="M1 10v108h57.22L91 85.09V10H1m80 70.96L54.07 108H11V20h70v60.96zM43 100h10V80h20V70H43v30M25 32h42v10H25V32zm0 18h42v10H25V50z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Document</span></span></a></li><li class="toc-list-entry-outline-padding"><a class="anchor u-truncate-anchor-text anchor-primary anchor-icon-left anchor-with-icon" href="#ecom0002" data-aa-button="sd:product:journal:article:type=anchor:region=outline:name=sdf" title="Document"><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-text-document"><path d="M1 10v108h57.22L91 85.09V10H1m80 70.96L54.07 108H11V20h70v60.96zM43 100h10V80h20V70H43v30M25 32h42v10H25V32zm0 18h42v10H25V50z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Document</span></span></a></li></ol><div class="PageDivider"></div></div></div></div><article class="col-lg-12 col-md-16 pad-left pad-right u-padding-s-top" lang="en"><div class="Publication" id="publication"><div class="publication-brand u-display-block-from-sm"><a class="anchor u-display-flex anchor-primary" href="/journal/annals-of-the-rheumatic-diseases" title="Go to Annals of the Rheumatic Diseases on ScienceDirect"><span class="anchor-text-container"><span class="anchor-text"><img class="publication-brand-image" src="/us-east-1/prod/2d348b415dc48b7aaa2f48d669a232bb69813c31/image/elsevier-non-solus.svg" alt="Elsevier"></span></span></a></div><div class="publication-volume u-text-center"><h2 class="publication-title u-h3" id="publication-title"><a class="anchor anchor-secondary publication-title-link" href="/journal/annals-of-the-rheumatic-diseases" title="Go to Annals of the Rheumatic Diseases on ScienceDirect"><span class="anchor-text-container"><span class="anchor-text">Annals of the Rheumatic Diseases</span></span></a></h2><div class="text-xs"><a class="anchor anchor-primary" href="/journal/annals-of-the-rheumatic-diseases/vol/84/issue/10" title="Go to table of contents for this volume/issue"><span class="anchor-text-container"><span class="anchor-text">Volume 84, Issue 10</span></span></a>, <!-- -->October 2025<!-- -->, Pages 1733-1742</div></div><div class="publication-cover u-display-block-from-sm"><a class="anchor u-display-flex anchor-primary" href="/journal/annals-of-the-rheumatic-diseases/vol/84/issue/10"><span class="anchor-text-container"><span class="anchor-text"><img class="publication-cover-image" src="https://ars.els-cdn.com/content/image/1-s2.0-S0003496725X00121-cov150h.gif" alt="Annals of the Rheumatic Diseases"></span></span></a></div></div><h1 id="screen-reader-main-title" class="Head u-font-serif u-h2 u-margin-s-ver"><div class="article-dochead"><span>Vasculitis</span></div><span class="title-text">Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis</span></h1><div class="Banner" id="banner"><div class="wrapper truncated"><div aria-live="polite"></div><div class="AuthorGroups"><div class="author-group" id="author-group"><span class="sr-only">Author links open overlay panel</span><button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0001" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xiaochuan</span> <span class="text surname">Sun</span> </span><span class="author-ref" id="baff0001"><sup>1</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0002" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Jing</span> <span class="text surname">Li</span> </span><span class="author-ref" id="baff0002"><sup>2</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0003" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xinwang</span> <span class="text surname">Duan</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0004" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Yahong</span> <span class="text surname">Wang</span> </span><span class="author-ref" id="baff0004"><sup>4</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0005" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Yu</span> <span class="text surname">Chen</span> </span><span class="author-ref" id="baff0005"><sup>5</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0006" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Ying</span> <span class="text surname">Wang</span> </span><span class="author-ref" id="baff0004"><sup>4</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0007" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Liyun</span> <span class="text surname">Zhang</span> </span><span class="author-ref" id="baff0006"><sup>6</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0008" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Dongyun</span> <span class="text surname">Yao</span> </span><span class="author-ref" id="baff0007"><sup>7</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0009" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Jing</span> <span class="text surname">Xue</span> </span><span class="author-ref" id="baff0008"><sup>8</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0010" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Zhenbiao</span> <span class="text surname">Wu</span> </span><span class="author-ref" id="baff0009"><sup>9</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0011" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Yi</span> <span class="text surname">Zhao</span> </span><span class="author-ref" id="baff0010"><sup>10</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0012" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Li</span> <span class="text surname">Luo</span> </span><span class="author-ref" id="baff0011"><sup>11</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0013" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Hongfeng</span> <span class="text surname">Zhang</span> </span><span class="author-ref" id="baff0012"><sup>12</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0014" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xiuling</span> <span class="text surname">Zhang</span> </span><span class="author-ref" id="baff0003"><sup>3</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0015" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Lili</span> <span class="text surname">Pan</span> </span><span class="author-ref" id="baff0013"><sup>13</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0016" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xiaofeng</span> <span class="text surname">Zeng</span> </span><span class="author-ref" id="baff0002"><sup>2</sup></span></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0017" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Mengtao</span> <span class="text surname">Li</span> </span><span class="author-ref" id="baff0002"><sup>2</sup></span><svg focusable="false" viewBox="0 0 106 128" height="20" title="Correspondence author icon" class="icon icon-person react-xocs-author-icon u-fill-grey8"><path d="M11.07 120l.84-9.29C13.88 91.92 35.25 87.78 53 87.78c17.74 0 39.11 4.13 41.08 22.84l.84 9.38h10.04l-.93-10.34C101.88 89.23 83.89 78 53 78S4.11 89.22 1.95 109.73L1.04 120h10.03M53 17.71c-9.72 0-18.24 8.69-18.24 18.59 0 13.67 7.84 23.98 18.24 23.98S71.24 49.97 71.24 36.3c0-9.9-8.52-18.59-18.24-18.59zM53 70c-15.96 0-28-14.48-28-33.67C25 20.97 37.82 8 53 8s28 12.97 28 28.33C81 55.52 68.96 70 53 70"></path></svg><svg focusable="false" viewBox="0 0 102 128" height="20" title="Author email or social media contact details icon" class="icon icon-envelope react-xocs-author-icon u-fill-grey8"><path d="M55.8 57.2c-1.78 1.31-5.14 1.31-6.9 0L17.58 34h69.54L55.8 57.19zM0 32.42l42.94 32.62c2.64 1.95 6.02 2.93 9.4 2.93s6.78-.98 9.42-2.93L102 34.34V24H0zM92 88.9L73.94 66.16l-8.04 5.95L83.28 94H18.74l18.38-23.12-8.04-5.96L10 88.94V51.36L0 42.9V104h102V44.82l-10 8.46V88.9"></path></svg></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0018" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Peter A.</span> <span class="text surname">Merkel</span> </span><span class="author-ref" id="baff0014"><sup>14</sup></span><svg focusable="false" viewBox="0 0 106 128" height="20" title="Correspondence author icon" class="icon icon-person react-xocs-author-icon u-fill-grey8"><path d="M11.07 120l.84-9.29C13.88 91.92 35.25 87.78 53 87.78c17.74 0 39.11 4.13 41.08 22.84l.84 9.38h10.04l-.93-10.34C101.88 89.23 83.89 78 53 78S4.11 89.22 1.95 109.73L1.04 120h10.03M53 17.71c-9.72 0-18.24 8.69-18.24 18.59 0 13.67 7.84 23.98 18.24 23.98S71.24 49.97 71.24 36.3c0-9.9-8.52-18.59-18.24-18.59zM53 70c-15.96 0-28-14.48-28-33.67C25 20.97 37.82 8 53 8s28 12.97 28 28.33C81 55.52 68.96 70 53 70"></path></svg><svg focusable="false" viewBox="0 0 102 128" height="20" title="Author email or social media contact details icon" class="icon icon-envelope react-xocs-author-icon u-fill-grey8"><path d="M55.8 57.2c-1.78 1.31-5.14 1.31-6.9 0L17.58 34h69.54L55.8 57.19zM0 32.42l42.94 32.62c2.64 1.95 6.02 2.93 9.4 2.93s6.78-.98 9.42-2.93L102 34.34V24H0zM92 88.9L73.94 66.16l-8.04 5.95L83.28 94H18.74l18.38-23.12-8.04-5.96L10 88.94V51.36L0 42.9V104h102V44.82l-10 8.46V88.9"></path></svg></span></span></button>, <button class="button-link button-link-secondary button-link-underline" type="button" data-sd-ui-side-panel-opener="true" data-xocs-content-type="author" data-xocs-content-id="au0019" aria-haspopup="dialog"><span class="button-link-text-container"><span class="button-link-text"><span class="react-xocs-alternative-link"><span class="given-name">Xinping</span> <span class="text surname">Tian</span> </span><span class="author-ref" id="baff0002"><sup>2</sup></span><svg focusable="false" viewBox="0 0 106 128" height="20" title="Correspondence author icon" class="icon icon-person react-xocs-author-icon u-fill-grey8"><path d="M11.07 120l.84-9.29C13.88 91.92 35.25 87.78 53 87.78c17.74 0 39.11 4.13 41.08 22.84l.84 9.38h10.04l-.93-10.34C101.88 89.23 83.89 78 53 78S4.11 89.22 1.95 109.73L1.04 120h10.03M53 17.71c-9.72 0-18.24 8.69-18.24 18.59 0 13.67 7.84 23.98 18.24 23.98S71.24 49.97 71.24 36.3c0-9.9-8.52-18.59-18.24-18.59zM53 70c-15.96 0-28-14.48-28-33.67C25 20.97 37.82 8 53 8s28 12.97 28 28.33C81 55.52 68.96 70 53 70"></path></svg><svg focusable="false" viewBox="0 0 102 128" height="20" title="Author email or social media contact details icon" class="icon icon-envelope react-xocs-author-icon u-fill-grey8"><path d="M55.8 57.2c-1.78 1.31-5.14 1.31-6.9 0L17.58 34h69.54L55.8 57.19zM0 32.42l42.94 32.62c2.64 1.95 6.02 2.93 9.4 2.93s6.78-.98 9.42-2.93L102 34.34V24H0zM92 88.9L73.94 66.16l-8.04 5.95L83.28 94H18.74l18.38-23.12-8.04-5.96L10 88.94V51.36L0 42.9V104h102V44.82l-10 8.46V88.9"></path></svg></span></span></button></div></div></div><button class="button-link u-margin-s-ver button-link-primary button-link-icon-right" type="button" id="show-more-btn" data-aa-button="icon-expand"><span class="button-link-text-container"><span class="button-link-text">Show more</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button><div class="banner-options u-padding-xs-bottom"><div class="toc-button-wrap u-display-inline-block u-display-none-from-lg u-margin-s-right"><button class="button-link button-link-secondary button-link-icon-left button-link-has-colored-icon" type="button"><svg focusable="false" viewBox="0 0 128 128" height="20" class="icon icon-list"><path d="M23 26a9 9 0 0 0-9 9 9 9 0 0 0 9 9 9 9 0 0 0 9-9 9 9 0 0 0-9-9zm23 4v10h68V30zM23 56a9 9 0 0 0-9 9 9 9 0 0 0 9 9 9 9 0 0 0 9-9 9 9 0 0 0-9-9zm23 4v10h68V60zM23 86a9 9 0 0 0-9 9 9 9 0 0 0 9 9 9 9 0 0 0 9-9 9 9 0 0 0-9-9zm23 4v10h68V90z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Outline</span></span></button></div><button class="button-link AddToMendeley button-link-secondary u-margin-s-right u-display-inline-flex-from-md button-link-icon-left button-link-has-colored-icon" type="button"><svg focusable="false" viewBox="0 0 86 128" height="20" class="icon icon-plus"><path d="M48 58V20H38v38H0v10h38v38h10V68h38V58z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Add to Mendeley</span></span></button><div class="Social u-display-inline-block" id="social"><div class="popover social-popover" id="social-popover"><div id="popover-trigger-social-popover"><button class="button-link button-link-secondary u-margin-s-right button-link-icon-left button-link-has-colored-icon" type="button" aria-expanded="false" aria-haspopup="true"><svg focusable="false" viewBox="0 0 114 128" height="20" class="icon icon-share"><path d="M90 112c-6.62 0-12-5.38-12-12s5.38-12 12-12 12 5.38 12 12-5.38 12-12 12zM24 76c-6.62 0-12-5.38-12-12s5.38-12 12-12 12 5.38 12 12-5.38 12-12 12zm66-60c6.62 0 12 5.38 12 12s-5.38 12-12 12-12-5.38-12-12 5.38-12 12-12zm0 62c-6.56 0-12.44 2.9-16.48 7.48L45.1 70.2c.58-1.98.9-4.04.9-6.2s-.32-4.22-.9-6.2l28.42-15.28C77.56 47.1 83.44 50 90 50c12.14 0 22-9.86 22-22S102.14 6 90 6s-22 9.86-22 22c0 1.98.28 3.9.78 5.72L40.14 49.1C36.12 44.76 30.38 42 24 42 11.86 42 2 51.86 2 64s9.86 22 22 22c6.38 0 12.12-2.76 16.14-7.12l28.64 15.38c-.5 1.84-.78 3.76-.78 5.74 0 12.14 9.86 22 22 22s22-9.86 22-22-9.86-22-22-22z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Share</span></span></button></div></div></div><div class="ExportCitation u-display-inline-block" id="export-citation"><div class="popover export-citation-popover" id="export-citation-popover"><div id="popover-trigger-export-citation-popover"><button class="button-link button-link-secondary button-link-icon-left button-link-has-colored-icon" type="button" aria-expanded="false" aria-haspopup="true"><svg focusable="false" viewBox="0 0 104 128" height="20" class="icon icon-cited-by-66"><path d="M2 58.78V106h44V64H12v-5.22C12 40.28 29.08 32 46 32V22C20.1 22 2 37.12 2 58.78zM102 32V22c-25.9 0-44 15.12-44 36.78V106h44V64H68v-5.22C68 40.28 85.08 32 102 32z"></path></svg><span class="button-link-text-container"><span class="button-link-text">Cite</span></span></button></div></div></div></div></div><div class="ArticleIdentifierLinks u-margin-xs-bottom text-xs" id="article-identifier-links"><a class="anchor doi anchor-primary" href="https://doi.org/10.1016/j.ard.2025.07.018" target="_blank" rel="noreferrer noopener" aria-label="Persistent link using digital object identifier" title="Persistent link using digital object identifier"><span class="anchor-text-container"><span class="anchor-text">https://doi.org/10.1016/j.ard.2025.07.018</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor rights-and-content anchor-primary" href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S000349672504289X&amp;orderBeanReset=true" target="_blank" rel="noreferrer noopener"><span class="anchor-text-container"><span class="anchor-text">Get rights and content</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div><div class="LicenseInfo text-xs u-margin-xs-bottom"><div class="License"><span>Under a Creative Commons </span><a class="anchor anchor-primary" href="http://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noreferrer noopener"><span class="anchor-text-container"><span class="anchor-text">license</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div><div class="AccessLabel"><span class="access-indicator"></span>Open access</div></div><section class="ReferencedArticles"></section><section class="ReferencedArticles"></section><div class="PageDivider"></div><div class="Abstracts u-font-serif" id="abstracts"><div class="abstract author" id="abs0001"><h2 class="section-title u-h4 u-margin-l-top u-margin-xs-bottom">ABSTRACT</h2><div id="abss0001"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0002">Objectives</h3><div class="u-margin-s-bottom" id="spara011">Study the efficacy and safety of mycophenolate mofetil (MMF) combined with methotrexate (MTX) compared to cyclophosphamide (CYC) followed by azathioprine (AZA) to treat active Takayasu arteritis (TAK).</div></div><div id="abss0002"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0003">Methods</h3><div class="u-margin-s-bottom" id="spara012">Adults with active TAK were randomised in a 2:1 ratio to receive oral MMF plus MTX or intravenous CYC followed by oral AZA. All subjects also received high-dose oral glucocorticoids with a predefined taper. The primary endpoint was overall response rate at week 52, defined as achieving a complete response (CR) or partial response (PR). Secondary endpoints included rates of CR and PR at weeks 28 and 52.</div></div><div id="abss0003"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0004">Results</h3><div class="u-margin-s-bottom" id="spara013">A total of 111 patients with TAK were enrolled: 74 in the MMF+MTX group and 37 in the CYC/AZA group, with comparable baseline demographic and clinical features. The overall response rates at 28 and 52 weeks were 58.1% and 55.4% in the MMF+MTX group, respectively, higher than 32.4% at both time points in the CYC/AZA group (<em>P</em> = .011 and .022). CR and PR rates at 28 and 52 weeks were also higher in the MMF+MTX group. Relapse occurred in 4 patients in the MMF+MTX group and 2 in the CYC/AZA group. One serious adverse event, neutropenia with fever, occurred in 1 patient in the CYC/AZA group.</div></div><div id="abss0004"><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="cesectitle0005">Conclusions</h3><div class="u-margin-s-bottom" id="spara014">Treatment of active TAK with MMF+MTX has more favourable efficacy compared to CYC/AZA. These findings provide evidence to use the combination of MTX and MMF, 2 generally well-tolerated and inexpensive therapies, to treat TAK.</div></div></div></div><ul id="issue-navigation" class="issue-navigation u-margin-s-bottom u-bg-grey1"><li class="previous move-left u-padding-s-ver u-padding-s-left"><a class="button-alternative button-alternative-tertiary u-display-flex button-alternative-icon-left" href="/science/article/pii/S000349672504172X"><svg focusable="false" viewBox="0 0 54 128" height="20" class="icon icon-navigate-left"><path d="M1 61l45-45 7 7-38 38 38 38-7 7z"></path></svg><span class="button-alternative-text-container"><span class="button-alternative-text">Previous <span class="extra-detail-1">article</span><span class="extra-detail-2"> in issue</span></span></span></a></li><li class="next move-right u-padding-s-ver u-padding-s-right"><a class="button-alternative button-alternative-tertiary u-display-flex button-alternative-icon-right" href="/science/article/pii/S0003496725042426"><span class="button-alternative-text-container"><span class="button-alternative-text">Next <span class="extra-detail-1">article</span><span class="extra-detail-2"> in issue</span></span></span><svg focusable="false" viewBox="0 0 54 128" height="20" class="icon icon-navigate-right"><path d="M1 99l38-38L1 23l7-7 45 45-45 45z"></path></svg></a></li></ul><div class="Body u-font-serif" id="body"><div><div class="u-margin-s-bottom" id="para9001"><span class="display"><div class="article-textbox" id="tbox0002" aria-label="Unlabelled box" role="region"><span id="tbcap1"><div class="u-margin-s-bottom" id="spara015">WHAT IS ALREADY KNOWN ON THIS TOPIC</div></span><div><div class="u-margin-s-bottom" id="para0007"><ul class="list"><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0008">The management of Takayasu arteritis (TAK) remains challenging due to the scarcity of high-quality, large-scale clinical studies, particularly randomised clinical trials (RCTs).</div></span></li><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0009">Cyclophosphamide (CYC) is commonly used to treat TAK but poses reproductive risks, which is particularly concerning given the predominance of TAK in women of childbearing age.</div></span></li><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0010">Mycophenolate mofetil (MMF) and methotrexate (MTX) have emerged as potential alternatives, though currently supported only by observational data.</div></span></li></ul></div><section id="sec0001"><h2 id="cesectitle0008" class="u-h4 u-margin-l-top u-margin-xs-bottom">WHAT THIS STUDY ADDS</h2><div class="u-margin-s-bottom" id="para0011"><ul class="list"><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0012">The CommittedTA trial is an open-label, multicentre RCT evaluating the efficacy and safety of MMF combined with MTX versus CYC followed by azathioprine in adults with active TAK.</div></span></li><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0013">This is only the second RCT investigating conventional disease-modifying antirheumatic drugs in TAK and the largest to date, enrolling 111 patients with this rare condition.</div></span></li><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0014">The trial demonstrated that MMF plus MTX has superior efficacy in inducing and maintaining remission, along with a more favourable safety profile over 52 weeks of treatment.</div></span></li></ul></div></section><section id="sec0002"><h2 id="cesectitle0009" class="u-h4 u-margin-l-top u-margin-xs-bottom">HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</h2><div class="u-margin-s-bottom" id="para0015"><ul class="list"><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0016">This study provides much-needed trial-level evidence and offers important clinical guidance for the management of TAK, particularly in resource-limited settings where access to biologics is limited.</div></span></li><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0017">The findings support the use of MMF plus MTX, 2 well-tolerated and affordable therapies to treat TAK.</div></span></li><li class="react-xocs-list-item"><span class="list-label">•</span><span class="list-content"><div class="u-margin-s-bottom" id="para0018">The trial also supports limiting the use of CYC in TAK treatment, considering both its relatively lower efficacy and its known reproductive toxicity.</div></span></li></ul></div></section></div></div></span></div><section id="sec0003"><h2 id="cesectitle0010" class="u-h4 u-margin-l-top u-margin-xs-bottom">INTRODUCTION</h2><div class="u-margin-s-bottom" id="para0019">Takayasu arteritis (TAK) is a rare chronic systemic vasculitis of the aorta and its major branches. TAK predominantly affects young women and typically has an insidious onset, triggering systemic inflammation and arterial damage that can lead to irreversible organ damage and even life-threatening events [<a class="anchor anchor-primary" href="#bib0001" name="bbib0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0001"><span class="anchor-text-container"><span class="anchor-text">1</span></span></a>]. Certain Asian regions, including China, bear a heavier disease burden of TAK compared to Western countries [<a class="anchor anchor-primary" href="#bib0002" name="bbib0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0002"><span class="anchor-text-container"><span class="anchor-text">2</span></span></a>].</div><div class="u-margin-s-bottom" id="para0020">Managing TAK is challenging due to the scarcity of high-quality, large-scale clinical studies, particularly randomised clinical trials (RCTs) [<a class="anchor anchor-primary" href="#bib0003" name="bbib0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0003"><span class="anchor-text-container"><span class="anchor-text">3</span></span></a>]. Current therapeutic approaches are primarily adapted from treatments for other autoimmune diseases, especially other forms of systemic vasculitis. Although glucocorticoids (GCs) are the mainstay of first-line treatment for TAK, additional immunosuppressive drugs are often added to the treatment regimen to both more effectively treat disease and to allow for reduction of GCs [<a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">[4]</span></span></a>, <a class="anchor anchor-primary" href="#bib0005" name="bbib0005" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0005"><span class="anchor-text-container"><span class="anchor-text">[5]</span></span></a>, <a class="anchor anchor-primary" href="#bib0006" name="bbib0006" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0006"><span class="anchor-text-container"><span class="anchor-text">[6]</span></span></a>], including both the so-called traditional disease-modifying antirheumatic drugs and targeted biologic agents.</div><div class="u-margin-s-bottom" id="para0021">In some countries, cyclophosphamide (CYC) is a commonly used agent for TAK, given its perceived efficacy as an immunosuppressive agent and its relatively low cost of administration compared to biologic drugs. To reduce the cumulative dose and toxicity of CYC, it is often replaced by azathioprine (AZA) once remission is achieved. However, given the significant adverse effects of CYC, including bone marrow suppression, infertility, and increased risk of malignancies, it is imperative to identify effective treatment regimens with at least comparable or improved efficacy and lower toxicity to treat patients with TAK [<a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">4</span></span></a>].</div><div class="u-margin-s-bottom" id="para0022">Mycophenolate mofetil (MMF) and methotrexate (MTX) are promising alternative treatments to CYC due to their potent immunosuppressive effects, lack of impact on fertility, and suitability for long-term use. MMF has gradually replaced CYC in treating various severe rheumatic diseases, including systemic lupus erythematosus and systemic sclerosis. An observational study with a small sample size showed that MMF was effective in 80% of patients with active TAK with minimal adverse effects [<a class="anchor anchor-primary" href="#bib0007" name="bbib0007" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0007"><span class="anchor-text-container"><span class="anchor-text">7</span></span></a>]. Similarly, the use of MTX to treat TAK is supported by several case series [<a class="anchor anchor-primary" href="#bib0008" name="bbib0008" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0008"><span class="anchor-text-container"><span class="anchor-text">8</span></span></a>,<a class="anchor anchor-primary" href="#bib0009" name="bbib0009" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0009"><span class="anchor-text-container"><span class="anchor-text">9</span></span></a>]. Combining immunosuppressive agents is a common approach to treating systemic inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and many others.</div><div class="u-margin-s-bottom" id="para0023">This clinical trial aimed to evaluate the efficacy and safety of GCs+MMF+MTX (experimental group) compared to GCs+CYC followed by GCs+AZA (control group) in treating active TAK.</div></section><section id="sec0004"><h2 id="cesectitle0011" class="u-h4 u-margin-l-top u-margin-xs-bottom">METHODS</h2><section id="sec0005"><h3 id="cesectitle0012" class="u-h4 u-margin-m-top u-margin-xs-bottom">Trial design</h3><div class="u-margin-s-bottom" id="para0024">This investigator-initiated, open-label, randomised controlled trial (the ‘CommittedTA’ trial) was conducted across 9 centres in China and registered on clinicaltrials.gov (NCT03096275). Patients with active TAK were recruited and randomised in a 2:1 ratio into the experimental (MMF+MTX) and active control (CYC/AZA) groups. The experimental group received MMF combined with MTX, while the control group received CYC followed by AZA. All subjects were followed for 52 weeks to evaluate the efficacy and safety of the treatments. MMF was supplied by Hunan Warrant Pharmaceutical, which had no role in the trial design, conduct, data analysis, or manuscript preparation. The trial was approved by the ethics committees at Peking Union Medical College Hospital and other participating sites. Written informed consent was obtained from each participant.</div></section><section id="sec0006"><h3 id="cesectitle0013" class="u-h4 u-margin-m-top u-margin-xs-bottom">Participants</h3><div class="u-margin-s-bottom" id="para0025">Patients were eligible if they met the 1990 American College of Rheumatology (ACR) classification criteria for TAK [<a class="anchor anchor-primary" href="#bib0010" name="bbib0010" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0010"><span class="anchor-text-container"><span class="anchor-text">10</span></span></a>], were at least 18 years old, and considered by the investigator to have active disease defined by at least 2 of the following 3 criteria: (1) one or more clinical manifestations of active disease; (2) one or more findings on imaging of progressive disease; or (3) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Clinical criteria included constitutional symptoms such as fever, fatigue, and weight loss, musculoskeletal symptoms, vascular pain, neurological or visual symptoms, abdominal pain or angina, new or worsening limb claudication, loss of pulses, and worsening hypertension. Imaging criteria included new or worsening vascular stenosis or aneurysms detected by ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography. Exclusion criteria involved prior use of MTX with dose reduction or discontinuation due to adverse events (AEs), discontinuation of MMF or CYC due to failed response or AEs, severe renal or liver disease, uncontrolled diabetes, hypertension, or heart failure, active infections, recent upper gastrointestinal bleeding, heterozygosity or homozygosity for the <em>TPMT</em> gene mutation, current or planned pregnancy during the trial period, severe coronary artery disease, or severe involvement of large head and neck vessels requiring urgent invasive procedures.</div></section><section id="sec0007"><h3 id="cesectitle0014" class="u-h4 u-margin-m-top u-margin-xs-bottom">Randomisation</h3><div class="u-margin-s-bottom" id="para0026">Patients were randomly assigned in a 2:1 ratio to receive MMF combined with MTX or CYC followed by AZA without masking. The randomisation process was performed on the RheumCloud App supported by the Chinese Rheumatism Data Center [<a class="anchor anchor-primary" href="#bib0011" name="bbib0011" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0011"><span class="anchor-text-container"><span class="anchor-text">11</span></span></a>].</div></section><section id="sec0008"><h3 id="cesectitle0015" class="u-h4 u-margin-m-top u-margin-xs-bottom">Interventions</h3><div class="u-margin-s-bottom" id="para0027">All study subjects received high-dose GCs. Patients weighing less than 50 kg started prednisone 50 mg or equivalent dose of other GC daily, with a weekly reduction of 5 mg/d starting after 4 weeks, reaching 20 mg daily by week 12, followed by a weekly reduction of 2.5 mg/d until reaching 10 mg daily by week 16, the dose was maintained until week 52. Patients weighing 50 kg or more started prednisone 60 mg or equivalent dose of other GC daily, with a weekly reduction of 5 mg starting after 4 weeks, reaching 30 mg daily by week 8, followed by a weekly reduction of 2.5 mg/d until reaching 10 mg daily by week 16, the dose was maintained until week 52.</div><div class="u-margin-s-bottom" id="para0028">MMF was prescribed as 750 mg (body weight &lt;50 kg) or 1000 mg (body weight ≥50 kg) twice daily, and MTX was given orally as 15 mg weekly. CYC was intravenously infused at 15 mg/kg (maximum dose of 1200 mg) every 2 weeks for the first 3 doses and then every 3 weeks, for a total of 10 infusions, followed by oral AZA 100 mg daily from weeks 28 to 52.</div></section><section id="sec0009"><h3 id="cesectitle0016" class="u-h4 u-margin-m-top u-margin-xs-bottom">Withdrawal</h3><div class="u-margin-s-bottom" id="para0029">Patients were withdrawn from the study if they exhibited worsening ischaemia symptoms, new arterial lesions on imaging, or if ESR or CRP levels remained higher than twice the upper limit of normal after 6 months. Additionally, withdrawal occurred if patients required emergent surgery due to disease progression or demonstrated poor tolerance or noncompliance with the study treatment. Other conditions warranting early withdrawal were determined by the investigators.</div></section><section id="sec0010"><h3 id="cesectitle0017" class="u-h4 u-margin-m-top u-margin-xs-bottom">Measurement and endpoints</h3><div class="u-margin-s-bottom" id="para0030">Study visits occurred at baseline and weeks 4, 16, 28, 36, and 52 after the initiation of treatment. Demographic features, medical history, clinical symptoms, physical examinations, routine blood and urine tests, levels of CRP and ESR were obtained at baseline and each follow-up visit. Vascular Doppler ultrasonography was performed in all patients at baseline, week 28, and week 52. The mural thickness and lumen diameter of the accessible arteries (right and left carotid, vertebral, subclavian, axillary and renal arteries, mesenteric arteries, and descending and abdominal aorta) were measured. Cervical and aortic CTA were performed using a 64-slice or higher CT scanner in all patients at baseline and week 52. The scan range for cervical CTA extended from the aortic arch to the skull vertex, and for aortic CTA, from the thoracic inlet to the iliac bifurcation. Meglumine diatrizoate was injected via an antecubital vein at 4 to 5 mL/s: 50 mL for cervical CTA and 100 mL for aortic CTA, followed by a 30 to 40 mL saline flush, and scanning started when enhancement reached 100 to 150 HU. Pulmonary artery and coronary CTA were performed in patients presenting with symptoms indicative of potential involvement in these vascular territories; electrocardiogram gating was applied in coronary CTA. Vascular imaging was independently assessed in a standardised fashion at each participating centre by radiologists and ultrasonographers who specialise in vascular imaging.</div><div class="u-margin-s-bottom" id="para0031">The primary endpoint was the overall response rate at week 52. Secondary endpoints included response rates at weeks 28 and 52, relapse rates, and stability or improvement in imaging. Safety endpoints included the frequency of AEs. A complete response (CR) was defined as the complete resolution of signs and symptoms of active disease, normalisation of both ESR and CRP, no progression on imaging of involved arteries, and the dose of GC &lt;15 mg daily. A partial response (PR) was defined as the same as CR except that ESR and CRP were not normal but were lower than twice the upper limit of normal or decreased by 50% compared to baseline. Overall response is the combination of CR and PR. If withdrawal from the study or switch to a different therapy occurred due to poor efficacy of the original treatment, the patient was assumed not to have achieved remission at subsequent follow-up assessments. A major relapse was defined as the recurrence of active disease, indicated by either clinical features of ischaemia or new-onset or progression of vessel dilation, stenosis, or occlusion. A minor relapse was defined as the recurrence of active disease, not fulfilling the criteria for a major relapse.</div><div class="u-margin-s-bottom" id="para0032">Severe AEs included death, life-threatening events, irreversible organ damage, hospitalisation, or prolongation of existing hospitalisation. Other adverse reactions were classified as mild AEs.</div></section><section id="sec0011"><h3 id="cesectitle0018" class="u-h4 u-margin-m-top u-margin-xs-bottom">Sample size</h3><div class="u-margin-s-bottom" id="para0033">Sample size was calculated based on the hypothesis that an equivalence test for the overall remission rate at week 52 in 2 study arms. According to a previous study, the overall effective rate of therapy including MMF in treating TAK is 80% [<a class="anchor anchor-primary" href="#bib0006" name="bbib0006" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0006"><span class="anchor-text-container"><span class="anchor-text">6</span></span></a>]. Due to lack of data regarding the efficacy of CYC for the treatment of TAK, the reported 52% response rate for treatment with CYC for proliferative nephritis was used to estimate the sample size calculation [<a class="anchor anchor-primary" href="#bib0012" name="bbib0012" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0012"><span class="anchor-text-container"><span class="anchor-text">12</span></span></a>]. Comparable effectiveness of MMF+MTX versus CYC/AZA in treating TAK was assumed in this study. With a power of 90% and an alpha error of 5%, a minimum of 88 subjects in the MMF+MTX group and 44 subjects in the CYC/AZA group were required. After considering a potential dropout rate of 15%, the final sample size was 150 patients, including 100 in the experimental group and 50 in the control group.</div></section><section id="sec0012"><h3 id="cesectitle0019" class="u-h4 u-margin-m-top u-margin-xs-bottom">Statistical analysis</h3><div class="u-margin-s-bottom" id="para0034">Efficacy analyses were performed on the intention-to-treat (ITT) and per-protocol (PP) populations. The ITT population included all randomised subjects, while the PP population included those without substantial protocol deviations, including premature discontinuation of study medicine for more than 1 month, taking any biologic drugs, or failure of tapering the dose of GCs to 10 mg daily at week 52. Patients who prematurely changed treatment due to inefficacy were included in the PP population as per their group assignment. Subgroup analyses on efficacy were performed based on prior use of MTX and distribution of vascular lesions, according to both Numano classification and a validated classification based on cluster analytics [<a class="anchor anchor-primary" href="#bib0013" name="bbib0013" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0013"><span class="anchor-text-container"><span class="anchor-text">13</span></span></a>,<a class="anchor anchor-primary" href="#bib0014" name="bbib0014" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0014"><span class="anchor-text-container"><span class="anchor-text">14</span></span></a>]. Safety profile assessment was performed in all subjects who received any study treatment and reported AEs.</div><div class="u-margin-s-bottom" id="para0035">Data are presented using descriptive statistics: normally distributed data are represented by the mean and SD and non-normally distributed data are expressed by the median and IQR. Categorical variables are represented by counts and percentages. The Shapiro-Wilk test was used to examine whether the variables were normally distributed. Chi-square test, t-test, or median test were used to identify differences in demographical or clinical characteristics at baseline between the intervention (MMF+MTX) and control (CYC/AZA) groups. Chi-square test was used to compare the effectiveness and safety profiles. All statistical analyses were performed using SPSS ver. 26 and Graphpad Prism ver. 9.5.</div></section></section><section id="sec0013"><h2 id="cesectitle0020" class="u-h4 u-margin-l-top u-margin-xs-bottom">RESULTS</h2><section id="sec0014"><h3 id="cesectitle0021" class="u-h4 u-margin-m-top u-margin-xs-bottom">Patient population</h3><div class="u-margin-s-bottom"><div id="para0036">Between February 2017 and September 2021, 130 patients with active TAK were screened for eligibility at 9 clinical centres. Of these, 111 patients were enrolled: 74 were randomly assigned to the MMF+MTX group, and 37 to the CYC/AZA group. Twelve patients were excluded based on the exclusion criteria: 6 for failure to respond to prior treatment with CYC, 1 for failure to respond to prior treatment with MMF, 4 due to the presence of the TMPT gene mutation, and 1 for severe coronary artery involvement requiring urgent invasive intervention. Seven patients declined to participate in this trial. After enrolment, all subjects were re-evaluated according to the 2022 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria for TAK [<a class="anchor anchor-primary" href="#bib0015" name="bbib0015" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0015"><span class="anchor-text-container"><span class="anchor-text">15</span></span></a>]. Only 2 patients in the MMF+MTX group and 1 patient in the CYC/AZA group did not meet the 2022 criteria, both due to a lack of clinical criteria for active disease. However, all 3 of these patients had new or worsening imaging lesions and elevated inflammatory markers, with other potential causes excluded; therefore, their diagnoses of TAK were confirmed, and they were included in the analysis. In the MMF+MTX group, 11 patients were excluded from the PP population at week 52, including 4 due to AEs, 2 due to loss of follow-up, and 5 for other reasons. In the CYC/AZA group, 8 patients were excluded from the PP population at week 52, 5 due to AEs, and 3 for other reasons (<a class="anchor anchor-primary" href="#fig0001" name="bfig0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0001"><span class="anchor-text-container"><span class="anchor-text">Fig 1</span></span></a>).</div><figure class="figure text-xs" id="fig0001"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr1.jpg" height="536" alt="Figure 1" aria-describedby="cap0001"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr1_lrg.jpg" target="_blank" download="" title="Download high-res image (585KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (585KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr1.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0001"><p id="spara001"><span class="label">Figure 1</span>. Enrolment and randomisation of patients. AE, adverse event; AZA, azathioprine; CYC, cyclophosphamide; ITT, intention-to-treat; MMF, mycophenolate mofetil; MTX, methotrexate; PP, per-protocol.</p></span></span></figure></div><div class="u-margin-s-bottom"><div id="para0037">The baseline characteristics of the patients were comparable between the 2 study arms (<a class="anchor anchor-primary" href="#tbl0001" name="btbl0001" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0001"><span class="anchor-text-container"><span class="anchor-text">Table 1</span></span></a>). Ninety-five (85.6%) patients were women. The median age at recruitment and disease onset was 30.0 (26.0-33.0) and 27.0 (21.0-31.0) years, respectively, with a median disease duration of 1.4 (0.9-4.7) years. The median body weight was 55 kg and about one-fourth of the patients had a body weight less than 50 kg. Overall, 13 patients used MMF at a dose of 1.5 g daily due to their low body weights. Overall, 83 (74.8%) patients had relapsed, and 25.2% had new-onset disease. At baseline, 24 (21.6%) patients were currently using GCs, with a median dosage of 10 mg/d of prednisone or equivalent. Fourteen (12.6%) patients had previously used MTX and 2 (1.8%) patients had previously used biologic drugs: 1 with tocilizumab and 1 with a TNF inhibitor. The median baseline levels of serum CRP and ESR at baseline were 28.4 (10.5-59.1) mg/L and 46.5 (29.5-73.3) mm/h, respectively.</div><div class="tables rowsep-0 colsep-0 frame-topbot" id="tbl0001"><span class="captions text-s"><span id="cap0004"><p id="spara004"><span class="label">Table 1</span>. Characteristics of the study patients at entry into the trial</p></span></span><div class="groups"><table><thead><tr class="rowsep-1"><th scope="col" class="align-left valign-top" id="en0001">Characteristics</th><th scope="col" class="align-left valign-top" id="en0002">Mycophenolate mofetil + methotrexate (N = 74)</th><th scope="col" class="align-left valign-top" id="en0003">Cyclophosphamide followed by azathioprine (N = 37)</th><th scope="col" class="align-left valign-top" id="en0004"><em>P</em> value</th></tr></thead><tbody><tr><td class="align-left valign-top" id="en0005">Female sex, no. (%)</td><td class="align-left valign-top" id="en0006">61 (82.4%)</td><td class="align-left valign-top" id="en0007">34 (91.9%)</td><td class="align-left valign-top" id="en0008">.181</td></tr><tr><td class="align-left valign-top" id="en0009">Age at recruitment, median (IQR) (y)</td><td class="align-left valign-top" id="en0010">29.5 (24.0-33.0)</td><td class="align-left valign-top" id="en0011">32.0 (29.0-38.5)</td><td class="align-left valign-top" id="en0012">.253</td></tr><tr><td class="align-left valign-top" id="en0013">Age at disease onset, median (IQR) (y)</td><td class="align-left valign-top" id="en0014">26.5 (19.8-30.3)</td><td class="align-left valign-top" id="en0015">29.0 (25.0-32.5)</td><td class="align-left valign-top" id="en0016">.122</td></tr><tr><td class="align-left valign-top" id="en0017">Disease duration, median (IQR) (y)</td><td class="align-left valign-top" id="en0018">1.3 (0.9-5.1)</td><td class="align-left valign-top" id="en0019">1.6 (0.9-4.0)</td><td class="align-left valign-top" id="en0020">.638</td></tr><tr><td class="align-left valign-top" id="en0021">Body weight, median (IQR) (kg)</td><td class="align-left valign-top" id="en0022">55.0 (50.0-66.3)</td><td class="align-left valign-top" id="en0023">54.0 (50.0-62.5)</td><td class="align-left valign-top" id="en0024">.637</td></tr><tr><td class="align-left valign-top" id="en0025">BMI, median (IQR) (kg/m<sup>2</sup>)</td><td class="align-left valign-top" id="en0026">20.7 (18.5-23.4)</td><td class="align-left valign-top" id="en0027">20.3 (18.3-23.7)</td><td class="align-left valign-top" id="en0028">.946</td></tr><tr><td class="align-left valign-top" id="en0029">Numano classification, no. (%)</td><td class="align-left valign-top" id="en0030"></td><td class="align-left valign-top" id="en0031"></td><td class="align-left valign-top" id="en0032">.313</td></tr><tr><td class="align-left valign-top" id="en0033">&nbsp;I</td><td class="align-left valign-top" id="en0034">10 (13.5%)</td><td class="align-left valign-top" id="en0035">4 (11.1%)</td><td class="align-left valign-top" id="en0036"></td></tr><tr><td class="align-left valign-top" id="en0037">&nbsp;IIa</td><td class="align-left valign-top" id="en0038">7 (9.5%)</td><td class="align-left valign-top" id="en0039">8 (22.2%)</td><td class="align-left valign-top" id="en0040"></td></tr><tr><td class="align-left valign-top" id="en0041">&nbsp;IIb</td><td class="align-left valign-top" id="en0042">8 (10.8%)</td><td class="align-left valign-top" id="en0043">6 (16.7%)</td><td class="align-left valign-top" id="en0044"></td></tr><tr><td class="align-left valign-top" id="en0045">&nbsp;III</td><td class="align-left valign-top" id="en0046">0 (0%)</td><td class="align-left valign-top" id="en0047">0 (0%)</td><td class="align-left valign-top" id="en0048"></td></tr><tr><td class="align-left valign-top" id="en0049">&nbsp;IV</td><td class="align-left valign-top" id="en0050">2 (2.7%)</td><td class="align-left valign-top" id="en0051">1 (2.8%)</td><td class="align-left valign-top" id="en0052"></td></tr><tr><td class="align-left valign-top" id="en0053">&nbsp;V</td><td class="align-left valign-top" id="en0054">47 (63.5%)</td><td class="align-left valign-top" id="en0055">17 (47.2%)</td><td class="align-left valign-top" id="en0056"></td></tr><tr><td class="align-left valign-top" id="en0057">New classification, no. (%)</td><td class="align-left valign-top" id="en0058"></td><td class="align-left valign-top" id="en0059"></td><td class="align-left valign-top" id="en0060">.695</td></tr><tr><td class="align-left valign-top" id="en0061">&nbsp;Cluster 1</td><td class="align-left valign-top" id="en0062">26 (35.1%)</td><td class="align-left valign-top" id="en0063">10 (27.0%)</td><td class="align-left valign-top" id="en0064"></td></tr><tr><td class="align-left valign-top" id="en0065">&nbsp;Cluster 2</td><td class="align-left valign-top" id="en0066">39 (52.7%)</td><td class="align-left valign-top" id="en0067">21 (56.8%)</td><td class="align-left valign-top" id="en0068"></td></tr><tr><td class="align-left valign-top" id="en0069">&nbsp;Cluster 3</td><td class="align-left valign-top" id="en0070">8 (10.8%)</td><td class="align-left valign-top" id="en0071">5 (13.5%)</td><td class="align-left valign-top" id="en0072"></td></tr><tr><td class="align-left valign-top" id="en0073">Pulmonary artery involvement, no. (%)</td><td class="align-left valign-top" id="en0074">8 (10.8%)</td><td class="align-left valign-top" id="en0075">4 (10.8%)</td><td class="align-left valign-top" id="en0076">1.000</td></tr><tr><td class="align-left valign-top" id="en0077">Coronary artery involvement, no. (%)</td><td class="align-left valign-top" id="en0078">1 (1.4%)</td><td class="align-left valign-top" id="en0079">1 (2.7%)</td><td class="align-left valign-top" id="en0080">1.000</td></tr><tr><td class="align-left valign-top" id="en0081">Relapsed patients, no. (%)</td><td class="align-left valign-top" id="en0082">52 (70.3%)</td><td class="align-left valign-top" id="en0083">31 (83.8%)</td><td class="align-left valign-top" id="en0084">.122</td></tr><tr><td class="align-left valign-top" id="en0085">History of invasive intervention, no. (%)</td><td class="align-left valign-top" id="en0086">12 (16.2%)</td><td class="align-left valign-top" id="en0087">3 (8.1%)</td><td class="align-left valign-top" id="en0088">.378</td></tr><tr><td class="align-left valign-top" id="en0089">Current use of glucocorticoids, no. (%)</td><td class="align-left valign-top" id="en0090">13 (17.8%)</td><td class="align-left valign-top" id="en0091">11 (30.6%)</td><td class="align-left valign-top" id="en0092">.146</td></tr><tr><td class="align-left valign-top" id="en0093">Glucocorticoid dose, median (IQR), mg/d of prednisone or equivalent</td><td class="align-left valign-top" id="en0094">10.0 (7.5-12.5)</td><td class="align-left valign-top" id="en0095">10.0 (5.0-15.0)</td><td class="align-left valign-top" id="en0096">.456</td></tr><tr><td class="align-left valign-top" id="en0097">Prior use of methotrexate, no. (%)</td><td class="align-left valign-top" id="en0098">7 (9.6%)</td><td class="align-left valign-top" id="en0099">7 (19.4%)</td><td class="align-left valign-top" id="en0100">.222</td></tr><tr><td class="align-left valign-top" id="en0101">Prior use of a biologic agent, no. (%)</td><td class="align-left valign-top" id="en0102">2 (2.7%)</td><td class="align-left valign-top" id="en0103">0 (0.0%)</td><td class="align-left valign-top" id="en0104">1.000</td></tr><tr><td class="align-left valign-top" id="en0105">WBC, median (IQR) (10<sup>9</sup>/L)</td><td class="align-left valign-top" id="en0106">8.3 (6.5-9.4)</td><td class="align-left valign-top" id="en0107">8.2 (6.7-10.9)</td><td class="align-left valign-top" id="en0108">1.000</td></tr><tr><td class="align-left valign-top" id="en0109">LYM, median (IQR) (10<sup>9</sup>/L)</td><td class="align-left valign-top" id="en0110">2.0 (1.5-2.3)</td><td class="align-left valign-top" id="en0111">2.0 (1.6-2.5)</td><td class="align-left valign-top" id="en0112">1.000</td></tr><tr><td class="align-left valign-top" id="en0113">CRP, median (IQR) (mg/L)</td><td class="align-left valign-top" id="en0114">27.8 (9.2-56.8)</td><td class="align-left valign-top" id="en0115">30.6 (11.7-62.3)</td><td class="align-left valign-top" id="en0116">.945</td></tr><tr><td class="align-left valign-top" id="en0117">ESR, median (IQR) (mm/h)</td><td class="align-left valign-top" id="en0118">45.5 (30.0-73.3)</td><td class="align-left valign-top" id="en0119">47.0 (23.5-77.5)</td><td class="align-left valign-top" id="en0120">.839</td></tr></tbody></table></div><div class="legend"><div class="u-margin-s-bottom" id="spara005">BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LYM, lymphocyte count; WBC, white blood cell count.</div></div></div></div></section><section id="sec0015"><h3 id="cesectitle0022" class="u-h4 u-margin-m-top u-margin-xs-bottom">Efficacy endpoints</h3><div class="u-margin-s-bottom"><div id="para0038">The primary endpoint, achieving an overall response at week 52, occurred in 41 of 74 patients (55.4%) in the MMF+MTX group and 12 of 37 patients (32.4%) in the CYC/AZA group, with an odds ratio (OR) of 2.59 (95% CI: 1.13-5.92, <em>P =</em> .022) (<a class="anchor anchor-primary" href="#tbl0002" name="btbl0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0002"><span class="anchor-text-container"><span class="anchor-text">Table 2</span></span></a> and <a class="anchor anchor-primary" href="#fig0002" name="bfig0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0002"><span class="anchor-text-container"><span class="anchor-text">Fig 2</span></span></a>). In the PP population, the overall response at week 52 was achieved by 37 of 63 patients (58.7%) in the MMF+MTX group and 12 of 29 patients (41.4%) in the CYC/AZA group, OR 2.02 (95% CI: 0.83-4.93, <em>P =</em> .121).</div><div class="tables rowsep-0 colsep-0 frame-topbot" id="tbl0002"><span class="captions text-s"><span id="cap0005"><p id="spara006"><span class="label">Table 2</span>. Response to treatment at 28 and 52 weeks by intention-to-treat and per-protocol analysis</p></span></span><div class="groups"><table><tbody><tr><th class="align-left valign-top" id="en0121" scope="row"><figure class="inline-figure"><img src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-fx1.jpg" height="436" alt="Image, table 2"></figure></th></tr></tbody></table></div><div class="legend"><div class="u-margin-s-bottom" id="spara007">AZA, azathioprine; CYC, cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate; OR, odds ratio.</div><div class="u-margin-s-bottom" id="spara008"><sup>a</sup>In the per-protocol population at week 28, 70 patients in the MMF+MTX group and 30 patients in the CYC/AZA group were included.</div></div></div><figure class="figure text-xs" id="fig0002"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr2.jpg" height="340" alt="Figure 2" aria-describedby="cap0002"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr2_lrg.jpg" target="_blank" download="" title="Download high-res image (212KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (212KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr2.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0002"><p id="spara002"><span class="label">Figure 2</span>. Response to treatment at 28 and 52 weeks by intention-to-treat analysis. AZA, azathioprine; CYC, cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate.</p></span></span></figure></div><div class="u-margin-s-bottom" id="para0039">With respect to secondary outcomes, CIs and <em>P</em> values were not adjusted for multiple comparisons. Both the CR and PR rates at week 52 were higher in the MMF+MTX group (41.9% and 13.5%, respectively) compared to the CYC/AZA group (29.7% and 2.7%, respectively), although these differences were not statistically significant. At week 28, 43 of 74 patients (58.1%) in the MMF+MTX group and 12 of 37 patients (32.4%) in the CYC/AZA group achieved an overall response, OR 2.89 (95% CI: 1.26-6.62, <em>P =</em> .011). A significantly higher PR rate at week 28 was observed in the MMF+MTX group compared to the CYC/AZA group (21.6% versus 5.4%, OR = 4.83, <em>P =</em> .031). The CR rate at week 28 was comparable between the 2 groups.</div><div class="u-margin-s-bottom" id="para0040">Although the conclusion regarding the primary endpoint was achieved, because the planned sample size was not reached, a post hoc power analysis was conducted for secondary endpoints. Specifically, for the differences in CR and PR at week 52, and CR at week 28 between the treatment groups, the estimated powers were 23.1%, 41.8%, and 16.1%, respectively, assuming a 2-sided alpha level of 0.05. Among those who achieved CR or PR at week 28 and week 52, all were maintained on 10 mg/d of prednisone or equivalent, a dosage aligned with the recommendations for maintenance of remission in TAK [<a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">[4]</span></span></a>, <a class="anchor anchor-primary" href="#bib0005" name="bbib0005" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0005"><span class="anchor-text-container"><span class="anchor-text">[5]</span></span></a>, <a class="anchor anchor-primary" href="#bib0006" name="bbib0006" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0006"><span class="anchor-text-container"><span class="anchor-text">[6]</span></span></a>]. The PP analysis yielded similar results (<a class="anchor anchor-primary" href="#tbl0002" name="btbl0002" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0002"><span class="anchor-text-container"><span class="anchor-text">Table 2</span></span></a>). A subgroup analysis based on disease phase (new-onset versus relapsed) was performed. In both subgroups, patients treated with MMF+MTX achieved higher overall response rates compared to CYC/AZA (59.1% versus 33.3% in new-onset patients; 58.8% versus 32.3% in relapsed patients). Although these differences were not statistically significant due to limited sample sizes, the direction and magnitude of treatment effects were consistent with the primary analysis.</div><div class="u-margin-s-bottom"><div id="para0041">Among patients who achieved an overall response at week 28, 1 patient (2.3%) in the MMF+MTX group experienced a relapse at week 36, and 3 patients (7.0%) relapsed by week 52. All 4 patients had elevated inflammatory markers, and 2 developed new-onset arterial stenosis and thickening. Two of the relapses were minor, both occurring in treatment-naïve patients; one was managed by increasing GC to the last effective dose, and the other by switching to a TNF inhibitor. The remaining 2 relapses were major and were managed with reinstitution of high-dose GC and a switch to alternative drugs. In the CYC/AZA group, 2 (16.7%) patients experienced major relapses at week 52. One patient had elevated inflammatory markers, and 2 patients showed progression on vessel thickening and stenosis. These relapses were managed with the reinstitution of high-dose GC and a switch to alternative drugs (<a class="anchor anchor-primary" href="#sec0024" name="bsec0024" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0024"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S1</span></span></a>). The changes in white blood cell counts, lymphocyte counts, CRP, ESR, and rates of patients with stable or improved imaging findings at weeks 28 and 52 were similar between the MMF+MTX and CYC/AZA groups (<a class="anchor anchor-primary" href="#fig0003" name="bfig0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fig0003"><span class="anchor-text-container"><span class="anchor-text">Fig 3</span></span></a> and <a class="anchor anchor-primary" href="#sec0024" name="bsec0024" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="sec0024"><span class="anchor-text-container"><span class="anchor-text">Supplementary Table S2</span></span></a>).</div><figure class="figure text-xs" id="fig0003"><span><img src="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr3.jpg" height="500" alt="Figure 3" aria-describedby="cap0003"><ol class="u-margin-s-bottom"><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr3_lrg.jpg" target="_blank" download="" title="Download high-res image (569KB)"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download high-res image (569KB)</span></span></span></a></li><li><a class="anchor download-link u-font-sans anchor-primary" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-gr3.jpg" target="_blank" download="" title="Download full-size image"><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download full-size image</span></span></span></a></li></ol></span><span class="captions text-s"><span id="cap0003"><p id="spara003"><span class="label">Figure 3</span>. Changes in levels of (A) white blood cell counts (WBC), (B) lymphocyte counts (LYM), (C) C-reactive protein (CRP), and (D) erythrocyte sedimentation rate (ESR) during the 52-week follow-up of patients in the (i) mycophenolate mofetil combined with methotrexate (MMF+MTX) and (ii) cyclophosphamide followed by azathioprine (CYC/AZA) treatment groups. Horizontal lines and boxes show the median and the 25th-75th percentile range of distribution; whiskers represent 10th-90th percentile.</p></span></span></figure></div></section><section id="sec0016"><h3 id="cesectitle0023" class="u-h4 u-margin-m-top u-margin-xs-bottom">Safety endpoints</h3><div class="u-margin-s-bottom"><div id="para0042">AEs were reported in 29 of 74 patients (39.2%) in the MMF+MTX group and 18 of 37 patients (48.6%) in the CYC/AZA group, <em>P =</em> .342. The most common AEs included abnormal liver function tests, gastrointestinal discomfort, and infections (<a class="anchor anchor-primary" href="#tbl0003" name="btbl0003" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tbl0003"><span class="anchor-text-container"><span class="anchor-text">Table 3</span></span></a>). Only 1 severe AE was documented in the CYC/AZA group in a patient who experienced neutropenia with fever and grade 4 thrombocytopenia after the initiation of AZA. This patient was immediately discontinued from the study treatment and supportive treatments were administered, including granulocyte colony-stimulating factor, thrombopoietin receptor agonist, and broad-spectrum antibiotics. The patient recovered without severe complications. All other AEs were mild.</div><div class="tables rowsep-0 colsep-0 frame-topbot" id="tbl0003"><span class="captions text-s"><span id="cap0006"><p id="spara009"><span class="label">Table 3</span>. Adverse events during the trial</p></span></span><div class="groups"><table><thead><tr class="rowsep-1"><th scope="col" class="align-left valign-top" id="en0122">Adverse events</th><th scope="col" class="align-left valign-top" id="en0123">Mycophenolate mofetil plus methotrexate (N = 74)</th><th scope="col" class="align-left valign-top" id="en0124">Cyclophosphamide followed by azathioprine (N = 37)</th><th scope="col" class="align-left valign-top" id="en0125">OR (95% CI)</th><th scope="col" class="align-left valign-top" id="en0126"><em>P</em> value</th></tr></thead><tbody><tr><td class="align-left valign-top" id="en0127">All adverse events</td><td class="align-left valign-top" id="en0128">29 (39.2%)</td><td class="align-left valign-top" id="en0129">18 (48.6%)</td><td class="align-left valign-top" id="en0130">0.68 (0.31-1.51)</td><td class="align-left valign-top" id="en0131">.342</td></tr><tr><td class="align-left valign-top" id="en0132">Severe adverse events</td><td class="align-left valign-top" id="en0133">0 (0%)</td><td class="align-left valign-top" id="en0134">1 (2.7%)<a class="anchor anchor-primary" href="#tb3fn1" name="btb3fn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb3fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>a</sup></span></span></a></td><td class="align-left valign-top" id="en0135">0.97 (0.92-1.03)</td><td class="align-left valign-top" id="en0136">.333</td></tr><tr><td class="align-left valign-top" id="en0137">Infection</td><td class="align-left valign-top" id="en0138">8 (10.8%)<a class="anchor anchor-primary" href="#tb3fn2" name="btb3fn2" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="tb3fn2"><span class="anchor-text-container"><span class="anchor-text"><sup>b</sup></span></span></a></td><td class="align-left valign-top" id="en0139">2 (5.4%)</td><td class="align-left valign-top" id="en0140">2.12 (0.43-10.54)</td><td class="align-left valign-top" id="en0141">.491</td></tr><tr><td class="align-left valign-top" id="en0142">Bone marrow suppression</td><td class="align-left valign-top" id="en0143">0 (0%)</td><td class="align-left valign-top" id="en0144">4 (10.8%)</td><td class="align-left valign-top" id="en0145">0.89 (0.80-1.00)</td><td class="align-left valign-top" id="en0146">.011</td></tr><tr><td class="align-left valign-top" id="en0147">Abnormal liver function</td><td class="align-left valign-top" id="en0148">17 (23.0%)</td><td class="align-left valign-top" id="en0149">5 (13.5%)</td><td class="align-left valign-top" id="en0150">1.91 (0.64-5.66)</td><td class="align-left valign-top" id="en0151">.239</td></tr><tr><td class="align-left valign-top" id="en0152">Gastrointestinal discomfort</td><td class="align-left valign-top" id="en0153">7 (9.5%)</td><td class="align-left valign-top" id="en0154">6 (16.2%)</td><td class="align-left valign-top" id="en0155">0.54 (0.17-1.74)</td><td class="align-left valign-top" id="en0156">.297</td></tr><tr><td class="align-left valign-top" id="en0157">Hair loss</td><td class="align-left valign-top" id="en0158">0 (0%)</td><td class="align-left valign-top" id="en0159">3 (8.1%)</td><td class="align-left valign-top" id="en0160">0.92 (0.84-1.01)</td><td class="align-left valign-top" id="en0161">.035</td></tr></tbody></table></div><div class="legend"><div class="u-margin-s-bottom" id="spara010">OR, odds ratio.</div></div><dl class="footnotes"><dt id="tb3fn1">a</dt><dd><div class="u-margin-s-bottom" id="notep0007">The patient experienced neutropenia with fever and grade 4 thrombocytopenia after the initiation of azathioprine. All other adverse events were mild.</div></dd><dt id="tb3fn2">b</dt><dd><div class="u-margin-s-bottom" id="notep0008">One patient in the mycophenolate mofetil + methotrexate group developed herpes zoster. All other infections in both groups were upper respiratory infections.</div></dd></dl></div></div><div class="u-margin-s-bottom" id="para0043">Infections were observed in 8 (10.8%) patients in the MMF+MTX group and 2 (5.4%) patients in the CYC/AZA group over the 52-week period, <em>P =</em> .491. One patient in the MMF+MTX group developed herpes zoster, while all other infections were upper respiratory tract infections. These infections were all mild and did not require intravenous antibiotics or hospitalisation. Bone marrow suppression and hair loss were reported only in the CYC/AZA group, in 4 (10.8%) patients and 3 (8.1%) patients, respectively. Four patients (10.8%) developed bone marrow suppression during treatment with AZA, including one severe case mentioned above. The other cases were mild and completely resolved after withdrawal of AZA, without complications such as infections or bleeding. Hair loss occurred in 3 patients (8.1%) during treatment of CYC and was mild and transient. Liver test abnormalities were more common in the MMF+MTX group, affecting 17 patients (23.0%). Four patients (5.4%) had alanine aminotransferase elevated 2 times the upper limit of normal and resulting in discontinuation of MTX. The remaining cases were mild and resolved without withdrawal of treatment regimens. Gastrointestinal discomfort was more frequently reported in the CYC/AZA group (6 patients, 16.2%) with all cases mild and the immunosuppressive treatments were not held or discontinued. The differences between groups in liver enzyme abnormalities and gastrointestinal discomfort were not statistically significant.</div></section></section><section id="sec0017"><h2 id="cesectitle0024" class="u-h4 u-margin-l-top u-margin-xs-bottom">DISCUSSION</h2><div class="u-margin-s-bottom" id="para0044">TAK is a chronic, systemic large-vessel vasculitis characterised by remissions and relapses. Although most patients with TAK achieve disease remission with treatment with high-dose GCs; however, nearly half of such patients will experience a disease relapse or progression during tapering of GCs [<a class="anchor anchor-primary" href="#bib0016" name="bbib0016" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0016"><span class="anchor-text-container"><span class="anchor-text">16</span></span></a>]. Therefore, early initiation of immunosuppressive agents in addition to GCs is suggested by both EULAR recommendations and ACR guidelines [<a class="anchor anchor-primary" href="#bib0004" name="bbib0004" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0004"><span class="anchor-text-container"><span class="anchor-text">4</span></span></a>,<a class="anchor anchor-primary" href="#bib0005" name="bbib0005" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0005"><span class="anchor-text-container"><span class="anchor-text">5</span></span></a>]. Despite the development of biological disease-modifying agents, conventional synthetic disease-modifying agents (csDMARDs) remain a mainstay of GC-sparing agents for TAK, especially in resource-limited areas. However, the choice of csDMARDs in the treatment of TAK is currently based on low-evidence data from observational studies with limited sample sizes or expert opinions, making these choices controversial [<a class="anchor anchor-primary" href="#bib0017" name="bbib0017" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0017"><span class="anchor-text-container"><span class="anchor-text">17</span></span></a>]. This RCT study compared the efficacy and safety of 2 regimens of csDMARDs to treat TAK: MMF+MTX versus CYC/AZA.</div><div class="u-margin-s-bottom" id="para0045">A prior questionnaire-based investigation indicated that CYC is commonly the first choice of csDMARDs for active TAK in China [<a class="anchor anchor-primary" href="#bib0018" name="bbib0018" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0018"><span class="anchor-text-container"><span class="anchor-text">18</span></span></a>]. However, this preference is mainly based on experience with other systemic vasculitides, such as ANCA-associated vasculitis, and not high-quality evidence from RCTs for TAK. Previous Chinese cohort studies reported that the effectiveness rates of CYC were 74% to 82% for treating TAK [<a class="anchor anchor-primary" href="#bib0019" name="bbib0019" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0019"><span class="anchor-text-container"><span class="anchor-text">19</span></span></a>,<a class="anchor anchor-primary" href="#bib0020" name="bbib0020" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0020"><span class="anchor-text-container"><span class="anchor-text">20</span></span></a>]. However, the current trial found that only one-third of patients responded well to treatment with CYC at 28 and 52 weeks. This discrepancy may be due to differences in patient selection as the previous studies included only treatment-naïve patients, whereas the majority of participants in the current trial had relapsed disease. Additionally, this trial adopted stricter criteria for remission and collected data in a protocolised prospective fashion. It is interesting that CYC is not as effective as expected in treating TAK despite being a potent immunosuppressive agent. CYC is also a drug to particularly avoid in treating TAK as most patients are females who present during their childbearing years.</div><div class="u-margin-s-bottom" id="para0046">MMF has shown promising efficacy for treating TAK in several studies. A meta-analysis of 2 cohort studies involving 31 patients demonstrated significant reductions in ESR, CRP, and GCs dose after treatment with MMF [<a class="anchor anchor-primary" href="#bib0021" name="bbib0021" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0021"><span class="anchor-text-container"><span class="anchor-text">21</span></span></a>]. A prospective study of 30 Chinese patients with TAK found that MMF combined with GCs was effective in 80% of patients [<a class="anchor anchor-primary" href="#bib0007" name="bbib0007" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0007"><span class="anchor-text-container"><span class="anchor-text">7</span></span></a>]. MTX is also commonly used to treat TAK, mainly supported by case series [<a class="anchor anchor-primary" href="#bib0008" name="bbib0008" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0008"><span class="anchor-text-container"><span class="anchor-text">8</span></span></a>,<a class="anchor anchor-primary" href="#bib0009" name="bbib0009" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0009"><span class="anchor-text-container"><span class="anchor-text">9</span></span></a>]. In a cohort study including 28 Chinese patients with initial-onset TAK, nearly 70% of patients achieved CR at 12 months with MTX at a dose of 10 to 15 mg weekly [<a class="anchor anchor-primary" href="#bib0022" name="bbib0022" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0022"><span class="anchor-text-container"><span class="anchor-text">22</span></span></a>]. Similarly, the current trial used a lower dose of MTX (15 mg weekly) compared to the typical dose used in Caucasian populations (20-25 mg weekly) due to the low body weight and tolerability of the medication in Chinese patients. Additionally, it is important to recognise that in this study MTX was combined with MMF; when drugs are combined, it is common to reduce the dose of one or both agents.</div><div class="u-margin-s-bottom" id="para0047">The 2018 EULAR recommendations suggest both MMF and MTX as potential first-line csDMARDs for TAK. However, previous studies were mainly uncontrolled cohorts or retrospective case series with limited sample sizes. A recent RCT comparing MMF and MTX for the treatment of TAK found that both drugs were effective and well-tolerated, with a response rate of 71% for MMF and 64% for MTX [<a class="anchor anchor-primary" href="#bib0023" name="bbib0023" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0023"><span class="anchor-text-container"><span class="anchor-text">23</span></span></a>]. Thus, evidence of the efficacy of these 2 medications or their combination for relapsed disease is lacking. In addition, the sample size of this prior study was small, and the duration of follow-up was short. The current trial provides the highest quality evidence to date of the effectiveness of MMF combined with MTX in treating TAK, with the largest sample size, and a randomised controlled design. The observed nearly 60% response rates at 28 and 52 weeks after treatment with MMF combined with MTX were significantly higher than those for treatment with CYC/AZA. Additionally, the relapse rate, particularly for major relapses, was also lower in the MMF+MTX group compared to the CYC/AZA group. However, given the limited sample size and relatively short follow-up duration, these findings warrant validation in future studies. All together, these results strongly support the use of MMF and MTX as csDMARDs over CYC to induce and maintain remission in TAK.</div><div class="u-margin-s-bottom" id="para0048">In this trial, the side effects of MMF+MTX and CYC/AZA were generally well-tolerated, except for 1 case of severe bone marrow suppression linked to AZA, and consistent with the known toxicities of these drugs. The risk of infection was similar between the 2 groups, with all infections being mild and not requiring intravenous antibiotics or hospitalisation. Liver test abnormalities were common in both treatment groups at similar rates, and all patients’ liver tests returned to normal after withdrawal of the study medications. Although not severe, bone marrow suppression, gastrointestinal discomfort, and hair loss were all more frequent in the CYC/AZA group.</div><div class="u-margin-s-bottom" id="para0049">This trial has several notable strengths. First, it is a randomised controlled trial with a large sample size for such a rare disease. The randomised design, together with the exclusion of biologic drugs and the implementation of a standardised GC tapering strategy, allowed for a more accurate comparison of the responses to MMF+MTX and CYC/AZA. Second, vascular ultrasound studies and CTA were performed regularly, enabling a comprehensive and objective assessment of disease activity. Third, despite the impact of the COVID-19 pandemic, the rates of loss to follow-up were quite low in both treatment arms, reducing potential selection bias. Lastly, the study adds to the limited pool of high-quality evidence regarding management of TAK and has strong clinical implications.</div><div class="u-margin-s-bottom" id="para0050">This study also has some limitations to consider. The sample size calculation was based on efficacy estimates from studies of lupus nephritis, which may not be directly transferable to studies of TAK. The efficacy of lupus nephritis was used as the reference for sample size calculation was due to the lack of data in patients with TAK; using the high estimates of efficacy in lupus nephritis to ensure a conservative sample size calculation by assuming a smaller treatment difference. This approach may have helped increase the power of this trial, but the evidence to support the sample size calculation is weak. Because the intended sample size was not reached, primarily due to the COVID-19 pandemic which made the access to nonemergent medical services difficult, the study period was extended to about 5 years. Nevertheless, the sample size was sufficient to compare the primary endpoints between the 2 study arms. Although the differences in some secondary endpoints did not reach statistical significance, this may be attributable to the insufficient statistical power caused by reduced sample size, suggesting that these negative findings should be interpreted with caution. Future studies with larger sample sizes are warranted to validate these findings. Additionally, the follow-up period was 52 weeks, which is relatively short for a chronic disease prone to relapse, although this was similar or longer compared to prior trials in TAK [<a class="anchor anchor-primary" href="#bib0023" name="bbib0023" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0023"><span class="anchor-text-container"><span class="anchor-text">[23]</span></span></a>, <a class="anchor anchor-primary" href="#bib0024" name="bbib0024" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0024"><span class="anchor-text-container"><span class="anchor-text">[24]</span></span></a>, <a class="anchor anchor-primary" href="#bib0025" name="bbib0025" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="bib0025"><span class="anchor-text-container"><span class="anchor-text">[25]</span></span></a>]. The long-term efficacy of MMF+MTX in maintaining remission remains uncertain and should be investigated in future studies with longer follow-up periods. The majority of trial participants had relapsed disease, possibly partially explaining the low overall response rate, and highlighting the challenges in managing relapsing TAK. However, it is patients with more extensive and relapsing disease who are the most in need of treatment with extended courses of immunosuppressive drugs. The open-label design in this trial may have introduced bias in outcome assessment. To minimise this risk, all patients underwent standardised evaluations at every visit, including comprehensive physical examinations and laboratory tests for inflammation. Additionally, vascular ultrasound and CTA were repeated and interpreted by physicians who were blinded to treatment allocation. Importantly, disease activity assessment was based on a combination of objective indicators, such as clinical symptoms and signs, inflammatory biomarkers, and imaging findings, rather than subjective reports alone. These measures substantially reduce the potential bias caused by the open-label design. Vascular imaging was not centrally reviewed; however, standardised protocols were applied at each participating centre. Lastly, as the analyses of CR and PR were secondary and exploratory, and given that the 2 are mutually exclusive and related, the risk of type I error inflation is lower than testing multiple independent outcomes, although should always be considered a possibility.</div><div class="u-margin-s-bottom" id="para0051">In conclusion, this 52-week RCT comparing treatment of TAK with MMF+ MTX versus CYC/AZA demonstrated that MMF+MTX has more favourable efficacy in inducing and maintaining remission and a superior safety profile. These results provide much-needed trial-level evidence for immunosuppressive treatments in TAK, including the use of drugs that are currently much less expensive than biologic agents, an important factor in many countries with high prevalences of TAK.</div></section></div><section id="coi0001"><h2 id="cesectitle0031" class="u-h4 u-margin-l-top u-margin-xs-bottom">Competing interests</h2><div class="u-margin-s-bottom" id="para0060">PAM reports receiving funds for the following activities in the past 2 years: Consulting: AbbVie, Alpine, Amgen, ArGenx, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL Behring, GlaxoSmithKline, iCell, Interius, Kinevant, Kyverna, Metagenomia, Neutrolis, Novartis, NS Pharma, Q32, Quell, Regeneron, Sanofi, Sparrow, Takeda, Vistera. Research support: AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eicos, Electra, GlaxoSmithKline, Neutrolis, Takeda. Stock options: Kyverna, Q32, Lifordi, Neutrolis, Sparrow. Royalties: UpToDate.</div></section><section id="sec0018"><h2 id="cesectitle0025" class="u-h4 u-margin-l-top u-margin-xs-bottom">Acknowledgements</h2><div class="u-margin-s-bottom" id="para0054">We thank the patients who participated in the CommittedTA trial for the time and effort they have invested in the project. We also thank the investigators, study nurses, patient partners and medical staff at the study centres for their contribution to study. We thank Professor Yanhong Wang for her support in statistical analysis. We thank the Hunan Warrant Pharmaceutical for supplying mycophenolate mofetil to study subjects, as well as the funding sources. This work was previously presented as an oral presentation at the ACR Convergence 2024 and published as a conference abstract: Sun X, Li J, Duan X, Zhang L, Yao D, Xue J, et al. Comparison of mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for active Takayasu’s arteritis: an open-label, randomized-controlled trial [abstract]. <em>Arthritis Rheumatol.</em> 2024 [cited 2025 Apr 20];76(suppl 9). Available from: <a class="anchor anchor-primary" href="https://acrabstracts.org/abstract/comparison-of-mycophenolate-mofetil-plus-methotrexate-versus-cyclophosphamide-with-sequential-azathioprine-for-active-takayasus-arteritis-an-open-label-randomized-controlled-trial/" target="_blank"><span class="anchor-text-container"><span class="anchor-text">https://acrabstracts.org/abstract/comparison-of-mycophenolate-mofetil-plus-methotrexate-versus-cyclophosphamide-with-sequential-azathioprine-for-active-takayasus-arteritis-an-open-label-randomized-controlled-trial/</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a>.</div></section><section id="sec0019"><h2 id="cesectitle0026" class="u-h4 u-margin-l-top u-margin-xs-bottom">Contributors</h2><div class="u-margin-s-bottom" id="para0055">XT, PAM, and ML designed the study and reviewed the manuscript. XT, JL, XD, LZ, DY, JX, ZW, YZ, LL, HZ, XZ, and LP recruited and enrolled participants and collected data. Yahong W, YC, and Ying W conducted the imaging tests. XS and JL collected, analysed and interpreted data, and wrote the report. XZ reviewed the manuscript. XT is guarantor and accepts full responsibility for the work and the conduct of the study, had access to the data and controlled the decision to publish.</div></section><section id="sec0020"><h2 id="cesectitle0027" class="u-h4 u-margin-l-top u-margin-xs-bottom">Funding</h2><div class="u-margin-s-bottom" id="para0056">This study was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-005, 2022-I2M-1-004, 2023-I2M-2-005), National High Level Hospital Clinical Research Funding (2022-PUMCH-B-013).</div></section><section id="sec0021"><h2 id="cesectitle0028" class="u-h4 u-margin-l-top u-margin-xs-bottom"><strong>Patient consent for publication</strong></h2><div class="u-margin-s-bottom" id="para0057">Written informed consent was obtained from each participant.</div></section><section id="sec0022"><h2 id="cesectitle0029" class="u-h4 u-margin-l-top u-margin-xs-bottom">Ethics approval</h2><div class="u-margin-s-bottom" id="para0058">The trial was approved by the ethics committees at Peking Union Medical College Hospital and other participating sites.</div></section><section id="sec0023"><h2 id="cesectitle0030" class="u-h4 u-margin-l-top u-margin-xs-bottom">Provenance and peer review</h2><div class="u-margin-s-bottom" id="para0059">Not commissioned; externally peer reviewed.</div></section><div class="Appendices"><section id="sec0025"><h2 id="cesectitle9002" class="u-h4 u-margin-l-top u-margin-xs-bottom">Appendix. Supplementary materials</h2><span class="download-all-supplemental-data"><span class="article-attachment"><iframe title="download_all" name="download_all" class="u-hide"></iframe><form method="post" action="/sdfe/pdf/download/S000349672504289X/attachments" target="download_all"><input name="eids" type="hidden" value="1-s2.0-S000349672504289X-mmc1.docx"><input name="eids" type="hidden" value="1-s2.0-S000349672504289X-mmc2.docx"><button class="button-link download-all-button u-font-sans button-link-primary button-link-icon-left" type="submit"><svg focusable="false" viewBox="0 0 98 128" height="20" class="icon icon-download"><path d="M77.38 56.18l-6.6-7.06L54 66.36V26H44v40.34L26.28 49.1l-7.3 7.08 29.2 29.32 29.2-29.32M88 74v20H10V74H0v30h98V74H88"></path></svg><span class="button-link-text-container"><span class="button-link-text"><span class="download-all-title">Download all </span>supplementary files<span class="u-show-inline-from-sm"> included with this article</span></span></span></button></form><a class="anchor help-link u-font-sans u-margin-s-left anchor-primary anchor-has-colored-icon anchor-icon-left anchor-with-icon" href="https://service.elsevier.com/app/answers/detail/a_id/19286/supporthub/sciencedirect/" target="_blank" title="What’s this? (Opens in new window)"><svg focusable="false" viewBox="0 0 114 128" height="20" class="icon icon-help"><path d="M57 8C35.69 7.69 15.11 21.17 6.68 40.71c-8.81 19.38-4.91 43.67 9.63 59.25 13.81 15.59 36.85 21.93 56.71 15.68 21.49-6.26 37.84-26.81 38.88-49.21 1.59-21.15-10.47-42.41-29.29-52.1C74.76 10.17 65.88 7.99 57 8zm0 10c20.38-.37 39.57 14.94 43.85 34.85 4.59 18.53-4.25 39.23-20.76 48.79-17.05 10.59-40.96 7.62-54.9-6.83-14.45-13.94-17.42-37.85-6.83-54.9C26.28 26.5 41.39 17.83 57 18zm-.14 14C45.31 32.26 40 40.43 40 50v2h10v-2c0-4.22 2.22-9.66 8-9.24 5.5.4 6.32 5.14 5.78 8.14C62.68 55.06 52 58.4 52 69.4V76h10v-5.56c0-8.16 11.22-11.52 12-21.7.74-9.86-5.56-16.52-16-16.74-.39-.01-.76-.01-1.14 0zM52 82v10h10V82H52z"></path></svg><span class="anchor-text-container"><span class="anchor-text">What’s this?</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></span></span><div class="u-margin-s-bottom" id="para0052a"><span class="display"><span class="e-component e-component-mmc1" id="ecom0001"><span class="article-attachment u-margin-xs-bottom"><a class="anchor download-link u-font-sans anchor-primary anchor-icon-left anchor-with-icon" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-mmc1.docx" target="_blank" download="" title="Download Word document (26KB)"><svg focusable="false" viewBox="0 0 92 128" height="20" width="20" class="icon icon-text-document"><path d="M1 10v108h57.22L91 85.09V10H1m80 70.96L54.07 108H11V20h70v60.96zM43 100h10V80h20V70H43v30M25 32h42v10H25V32zm0 18h42v10H25V50z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download Word document (26KB)</span></span></span></a></span></span></span><span class="display"><span class="e-component e-component-mmc2" id="ecom0002"><span class="article-attachment u-margin-xs-bottom"><a class="anchor download-link u-font-sans anchor-primary anchor-icon-left anchor-with-icon" href="https://ars.els-cdn.com/content/image/1-s2.0-S000349672504289X-mmc2.docx" target="_blank" download="" title="Download Word document (104KB)"><svg focusable="false" viewBox="0 0 92 128" height="20" width="20" class="icon icon-text-document"><path d="M1 10v108h57.22L91 85.09V10H1m80 70.96L54.07 108H11V20h70v60.96zM43 100h10V80h20V70H43v30M25 32h42v10H25V32zm0 18h42v10H25V50z"></path></svg><span class="anchor-text-container"><span class="anchor-text">Download: <span class="download-link-title">Download Word document (104KB)</span></span></span></a></span></span></span></div></section></div></div><div class="related-content-links u-display-none-from-md"><button class="button-link button-link-primary button-link-small" type="button"><span class="button-link-text-container"><span class="button-link-text">Recommended articles</span></span></button></div><div class="Tail"></div><div><section class="bibliography u-font-serif text-s" id="cebibl1"><h2 class="section-title u-h4 u-margin-l-top u-margin-xs-bottom">REFERENCES</h2><section class="bibliography-sec" id="cebibsec1"><ol class="references" id="reference-links-cebibsec1"><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0001" id="ref-id-bib0001" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[1]</span></span></a></span><span class="reference" id="sbref0001"><div class="contribution"><div class="authors u-font-sans">D. Pugh, M. Karabayas, N. Basu, M.C. Cid, R. Goel, C.S. Goodyear, <em> et al.</em></div><div id="ref-id-sbref0001" class="title text-m">Large-vessel vasculitis</div></div><div class="host u-font-sans">Nat Rev Dis Primers, 7 (2022), p. 93</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85122480300&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0001"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Large-vessel%20vasculitis&amp;publication_year=2022&amp;author=D.%20Pugh&amp;author=M.%20Karabayas&amp;author=N.%20Basu&amp;author=M.C.%20Cid&amp;author=R.%20Goel&amp;author=C.S.%20Goodyear" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0001"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0002" id="ref-id-bib0002" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[2]</span></span></a></span><span class="reference" id="sbref0002"><div class="contribution"><div class="authors u-font-sans">D. Danda, P. Manikuppam, X. Tian, M. Harigai</div><div id="ref-id-sbref0002" class="title text-m">Advances in Takayasu arteritis: an Asia Pacific perspective</div></div><div class="host u-font-sans">Front Med (Lausanne), 9 (2022), Article 952972</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85136842119&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0002"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Advances%20in%20Takayasu%20arteritis%3A%20an%20Asia%20Pacific%20perspective&amp;publication_year=2022&amp;author=D.%20Danda&amp;author=P.%20Manikuppam&amp;author=X.%20Tian&amp;author=M.%20Harigai" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0002"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0003" id="ref-id-bib0003" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[3]</span></span></a></span><span class="reference" id="sbref0003"><div class="contribution"><div class="authors u-font-sans">D.P. Misra, A. Wakhlu, V. Agarwal, D. Danda</div><div id="ref-id-sbref0003" class="title text-m">Recent advances in the management of Takayasu arteritis</div></div><div class="host u-font-sans">Int J Rheum Dis, 22 (suppl 1) (2019), pp. 60-68</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1111/1756-185x.13285" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0003"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85060806012&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0003"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Recent%20advances%20in%20the%20management%20of%20Takayasu%20arteritis&amp;publication_year=2019&amp;author=D.P.%20Misra&amp;author=A.%20Wakhlu&amp;author=V.%20Agarwal&amp;author=D.%20Danda" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0003"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0004" id="ref-id-bib0004" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[4]</span></span></a></span><span class="reference" id="sbref0004"><div class="contribution"><div class="authors u-font-sans">B. Hellmich, A. Agueda, S. Monti, F. Buttgereit, H. de Boysson, E. Brouwer, <em> et al.</em></div><div id="ref-id-sbref0004" class="title text-m">2018 Update of the EULAR recommendations for the management of large vessel vasculitis</div></div><div class="host u-font-sans">Ann Rheum Dis, 79 (1) (2020), pp. 19-30</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724015358/pdfft?md5=f2184577581846d835db2630fdcafdfb&amp;pid=1-s2.0-S0003496724015358-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0004"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724015358" aria-describedby="ref-id-sbref0004"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/annrheumdis-2019-215672" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0004"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=2018%20Update%20of%20the%20EULAR%20recommendations%20for%20the%20management%20of%20large%20vessel%20vasculitis&amp;publication_year=2020&amp;author=B.%20Hellmich&amp;author=A.%20Agueda&amp;author=S.%20Monti&amp;author=F.%20Buttgereit&amp;author=H.%20de%20Boysson&amp;author=E.%20Brouwer" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0004"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0005" id="ref-id-bib0005" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[5]</span></span></a></span><span class="reference" id="sbref0005"><div class="contribution"><div class="authors u-font-sans">M. Maz, S.A. Chung, A. Abril, C.A. Langford, M. Gorelik, G. Guyatt, <em> et al.</em></div><div id="ref-id-sbref0005" class="title text-m">2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis</div></div><div class="host u-font-sans">Arthritis Rheumatol, 73 (8) (2021), pp. 1349-1365</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1002/art.41774" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0005"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85109629743&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0005"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=2021%20American%20College%20of%20RheumatologyVasculitis%20Foundation%20Guideline%20for%20the%20management%20of%20giant%20cell%20arteritis%20and%20Takayasu%20arteritis&amp;publication_year=2021&amp;author=M.%20Maz&amp;author=S.A.%20Chung&amp;author=A.%20Abril&amp;author=C.A.%20Langford&amp;author=M.%20Gorelik&amp;author=G.%20Guyatt" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0005"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0006" id="ref-id-bib0006" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[6]</span></span></a></span><span class="reference" id="sbref0006"><div class="contribution"><div class="authors u-font-sans">X. Tian, X. Zeng</div><div id="ref-id-sbref0006" class="title text-m">Chinese guideline for the diagnosis and treatment of Takayasu’s arteritis (2023)</div></div><div class="host u-font-sans">Rheumatol Immunol Res, 5 (1) (2024), pp. 5-26</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1515/rir-2024-0002" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85189959130&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Chinese%20guideline%20for%20the%20diagnosis%20and%20treatment%20of%20Takayasus%20arteritis%20&amp;publication_year=2024&amp;author=X.%20Tian&amp;author=X.%20Zeng" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0006"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0007" id="ref-id-bib0007" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[7]</span></span></a></span><span class="reference" id="sbref0007"><div class="contribution"><div class="authors u-font-sans">J. Li, Y. Yang, J. Zhao, M. Li, X. Tian, X. Zeng</div><div id="ref-id-sbref0007" class="title text-m">The efficacy of mycophenolate mofetil for the treatment of Chinese Takayasu’s arteritis</div></div><div class="host u-font-sans">Sci Rep, 6 (2016), Article 38687</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85002857436&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0007"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=The%20efficacy%20of%20mycophenolate%20mofetil%20for%20the%20treatment%20of%20Chinese%20Takayasus%20arteritis&amp;publication_year=2016&amp;author=J.%20Li&amp;author=Y.%20Yang&amp;author=J.%20Zhao&amp;author=M.%20Li&amp;author=X.%20Tian&amp;author=X.%20Zeng" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0007"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0008" id="ref-id-bib0008" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[8]</span></span></a></span><span class="reference" id="sbref0008"><div class="contribution"><div class="authors u-font-sans">G.S. Hoffman, R.Y. Leavitt, G.S. Kerr, M. Rottem, M.C. Sneller, AS. Fauci</div><div id="ref-id-sbref0008" class="title text-m">Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate</div></div><div class="host u-font-sans">Arthritis Rheum, 37 (4) (1994), pp. 578-582</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1002/art.1780370420" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0008"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-0028258530&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0008"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Treatment%20of%20glucocorticoid-resistant%20or%20relapsing%20Takayasu%20arteritis%20with%20methotrexate&amp;publication_year=1994&amp;author=G.S.%20Hoffman&amp;author=R.Y.%20Leavitt&amp;author=G.S.%20Kerr&amp;author=M.%20Rottem&amp;author=M.C.%20Sneller&amp;author=AS.%20Fauci" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0008"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0009" id="ref-id-bib0009" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[9]</span></span></a></span><span class="reference" id="sbref0009"><div class="contribution"><div class="authors u-font-sans">D. Mevorach, G. Leibowitz, M. Brezis, E. Raz</div><div id="ref-id-sbref0009" class="title text-m">Induction of remission in a patient with Takayasu’s arteritis by low dose pulses of methotrexate</div></div><div class="host u-font-sans">Ann Rheum Dis, 51 (7) (1992), pp. 904-905</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S000349672403601X/pdf?md5=c73e16fca8213f7949b3f36cc318ff5f&amp;pid=1-s2.0-S000349672403601X-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0009"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S000349672403601X" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/ard.51.7.904" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-0026716113&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Induction%20of%20remission%20in%20a%20patient%20with%20Takayasus%20arteritis%20by%20low%20dose%20pulses%20of%20methotrexate&amp;publication_year=1992&amp;author=D.%20Mevorach&amp;author=G.%20Leibowitz&amp;author=M.%20Brezis&amp;author=E.%20Raz" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0009"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0010" id="ref-id-bib0010" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[10]</span></span></a></span><span class="reference" id="sbref0010"><div class="contribution"><div class="authors u-font-sans">W.P. Arend, B.A. Michel, D.A. Bloch, G.G. Hunder, L.H. Calabrese, S.M. Edworthy, <em> et al.</em></div><div id="ref-id-sbref0010" class="title text-m">The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis</div></div><div class="host u-font-sans">Arthritis Rheum, 33 (8) (1990), pp. 1129-1134</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1002/art.1780330811" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0010"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-0025042935&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0010"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=The%20American%20College%20of%20Rheumatology%201990%20criteria%20for%20the%20classification%20of%20Takayasu%20arteritis&amp;publication_year=1990&amp;author=W.P.%20Arend&amp;author=B.A.%20Michel&amp;author=D.A.%20Bloch&amp;author=G.G.%20Hunder&amp;author=L.H.%20Calabrese&amp;author=S.M.%20Edworthy" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0010"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0011" id="ref-id-bib0011" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[11]</span></span></a></span><span class="reference" id="sbref0011"><div class="contribution"><div class="authors u-font-sans">C. Huang, J. Zhao, X. Tian, Q. Wang, D. Xu, M. Li, <em> et al.</em></div><div id="ref-id-sbref0011" class="title text-m">RheumCloud app: a novel mobile application for the management of rheumatic diseases patients in China</div></div><div class="host u-font-sans">Rheumatol Immunol Res, 3 (4) (2022), pp. 184-189</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.2478/rir-2022-0033" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0011"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85174006215&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0011"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=RheumCloud%20app%3A%20a%20novel%20mobile%20application%20for%20the%20management%20of%20rheumatic%20diseases%20patients%20in%20China&amp;publication_year=2022&amp;author=C.%20Huang&amp;author=J.%20Zhao&amp;author=X.%20Tian&amp;author=Q.%20Wang&amp;author=D.%20Xu&amp;author=M.%20Li" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0011"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0012" id="ref-id-bib0012" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[12]</span></span></a></span><span class="reference" id="sbref0012"><div class="contribution"><div class="authors u-font-sans">L.M. Ong, L.S. Hooi, T.O. Lim, B.L. Goh, G. Ahmad, R. Ghazalli, <em> et al.</em></div><div id="ref-id-sbref0012" class="title text-m">Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis</div></div><div class="host u-font-sans">Nephrology (Carlton), 10 (5) (2005), pp. 504-510</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1111/j.1440-1797.2005.00444.x" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0012"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-28444437000&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0012"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Randomized%20controlled%20trial%20of%20pulse%20intravenous%20cyclophosphamide%20versus%20mycophenolate%20mofetil%20in%20the%20induction%20therapy%20of%20proliferative%20lupus%20nephritis&amp;publication_year=2005&amp;author=L.M.%20Ong&amp;author=L.S.%20Hooi&amp;author=T.O.%20Lim&amp;author=B.L.%20Goh&amp;author=G.%20Ahmad&amp;author=R.%20Ghazalli" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0012"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0013" id="ref-id-bib0013" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[13]</span></span></a></span><span class="reference" id="sbref0013"><div class="contribution"><div class="authors u-font-sans">A. Hata, M. Noda, R. Moriwaki, F. Numano</div><div id="ref-id-sbref0013" class="title text-m">Angiographic findings of Takayasu arteritis: new classification</div></div><div class="host u-font-sans">Int J Cardiol, 54 (1996), pp. S155-S163</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0167527396028136/pdf?md5=b3bfc011035596d0b97dac09126b6348&amp;pid=1-s2.0-S0167527396028136-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0013"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0167527396028136" aria-describedby="ref-id-sbref0013"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-0030203230&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0013"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Angiographic%20findings%20of%20Takayasu%20arteritis%3A%20new%20classification&amp;publication_year=1996&amp;author=A.%20Hata&amp;author=M.%20Noda&amp;author=R.%20Moriwaki&amp;author=F.%20Numano" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0013"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0014" id="ref-id-bib0014" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[14]</span></span></a></span><span class="reference" id="sbref0014"><div class="contribution"><div class="authors u-font-sans">R. Goel, K.B. Gribbons, S. Carette, D. Cuthbertson, G.S. Hoffman, G. Joseph, <em> et al.</em></div><div id="ref-id-sbref0014" class="title text-m">Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America</div></div><div class="host u-font-sans">Rheumatology (Oxford), 59 (2020), pp. 1118-1127</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1093/rheumatology/kez421" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85084167098&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Derivation%20of%20an%20angiographically%20based%20classification%20system%20in%20Takayasus%20arteritis%3A%20an%20observational%20study%20from%20India%20and%20North%20America&amp;publication_year=2020&amp;author=R.%20Goel&amp;author=K.B.%20Gribbons&amp;author=S.%20Carette&amp;author=D.%20Cuthbertson&amp;author=G.S.%20Hoffman&amp;author=G.%20Joseph" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0014"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0015" id="ref-id-bib0015" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[15]</span></span></a></span><span class="reference" id="sbref0015"><div class="contribution"><div class="authors u-font-sans">P.C. Grayson, C. Ponte, R. Suppiah, J.C. Robson, K.B. Gribbons, A. Judge, <em> et al.</em></div><div id="ref-id-sbref0015" class="title text-m">2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis</div></div><div class="host u-font-sans">Ann Rheum Dis, 81 (2022), pp. 1654-1660</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724087314/pdfft?md5=cdd2a35f503c5d7bf384284407c8a409&amp;pid=1-s2.0-S0003496724087314-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0015"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724087314" aria-describedby="ref-id-sbref0015"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/ard-2022-223482" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0015"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85141892081&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0015"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=2022%20American%20College%20of%20RheumatologyEULAR%20classification%20criteria%20for%20Takayasu%20arteritis&amp;publication_year=2022&amp;author=P.C.%20Grayson&amp;author=C.%20Ponte&amp;author=R.%20Suppiah&amp;author=J.C.%20Robson&amp;author=K.B.%20Gribbons&amp;author=A.%20Judge" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0015"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0016" id="ref-id-bib0016" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[16]</span></span></a></span><span class="reference" id="sbref0016"><div class="contribution"><div class="authors u-font-sans">C. Comarmond, L. Biard, M. Lambert, A. Mekinian, Y. Ferfar, J.E. Kahn, <em> et al.</em></div><div id="ref-id-sbref0016" class="title text-m">Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients</div></div><div class="host u-font-sans">Circulation, 136 (12) (2017), pp. 1114-1122</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85024476496&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0016"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Long-term%20outcomes%20and%20prognostic%20factors%20of%20complications%20in%20Takayasu%20arteritis%3A%20a%20multicenter%20study%20of%20318%20patients&amp;publication_year=2017&amp;author=C.%20Comarmond&amp;author=L.%20Biard&amp;author=M.%20Lambert&amp;author=A.%20Mekinian&amp;author=Y.%20Ferfar&amp;author=J.E.%20Kahn" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0016"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0017" id="ref-id-bib0017" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[17]</span></span></a></span><span class="reference" id="sbref0017"><div class="contribution"><div class="authors u-font-sans">F. Regola, M. Uzzo, P. Toniati, B. Trezzi, R.A. Sinico, F. Franceschini</div><div id="ref-id-sbref0017" class="title text-m">Novel therapies in Takayasu arteritis</div></div><div class="host u-font-sans">Front Med (Lausanne), 8 (2021), Article 814075</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85123401336&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0017"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Novel%20therapies%20in%20Takayasu%20arteritis&amp;publication_year=2021&amp;author=F.%20Regola&amp;author=M.%20Uzzo&amp;author=P.%20Toniati&amp;author=B.%20Trezzi&amp;author=R.A.%20Sinico&amp;author=F.%20Franceschini" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0017"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0018" id="ref-id-bib0018" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[18]</span></span></a></span><span class="reference" id="sbref0018"><div class="contribution"><div class="authors u-font-sans">X.M. Dai, Z.H. Dong, S. Chen, Y.J. Cheng, Z.Y. Da, S.M. Dai, <em> et al.</em></div><div id="ref-id-sbref0018" class="title text-m">Chinese expert investigation on diagnosis and disease activity evaluation in Takayasu’s arteritis</div></div><div class="host u-font-sans">Fudan Univ J Med Sci, 44 (2) (2017), pp. 127-133</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85020173694&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0018"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Chinese%20expert%20investigation%20on%20diagnosis%20and%20disease%20activity%20evaluation%20in%20Takayasus%20arteritis&amp;publication_year=2017&amp;author=X.M.%20Dai&amp;author=Z.H.%20Dong&amp;author=S.%20Chen&amp;author=Y.J.%20Cheng&amp;author=Z.Y.%20Da&amp;author=S.M.%20Dai" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0018"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0019" id="ref-id-bib0019" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[19]</span></span></a></span><span class="reference" id="sbref0019"><div class="contribution"><div class="authors u-font-sans">X. Dai, X. Cui, Y. Sun, L. Ma, L. Jiang</div><div id="ref-id-sbref0019" class="title text-m">Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu’s arteritis: an observational study</div></div><div class="host u-font-sans">Ther Adv Chronic Dis, 11 (2020), Article 2040622320922019</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Effectiveness%20and%20safety%20of%20leflunomide%20compared%20with%20cyclophosphamide%20as%20induction%20therapy%20in%20Takayasus%20arteritis%3A%20an%20observational%20study&amp;publication_year=2020&amp;author=X.%20Dai&amp;author=X.%20Cui&amp;author=Y.%20Sun&amp;author=L.%20Ma&amp;author=L.%20Jiang" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0019"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0020" id="ref-id-bib0020" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[20]</span></span></a></span><span class="reference" id="sbref0020"><div class="contribution"><div class="authors u-font-sans">S. Ying, C. Xiaomeng, D. Xiaomin, L. Jiang, L. Peng, M. Lili, <em> et al.</em></div><div id="ref-id-sbref0020" class="title text-m">Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study</div></div><div class="host u-font-sans">Ther Adv Musculoskelet Dis, 12 (2020)</div><div class="comment">1759720X20930114</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20leflunomide%20versus%20cyclophosphamide%20for%20initial-onset%20Takayasu%20arteritis%3A%20a%20prospective%20cohort%20study&amp;publication_year=2020&amp;author=S.%20Ying&amp;author=C.%20Xiaomeng&amp;author=D.%20Xiaomin&amp;author=L.%20Jiang&amp;author=L.%20Peng&amp;author=M.%20Lili" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0020"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0021" id="ref-id-bib0021" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[21]</span></span></a></span><span class="reference" id="sbref0021"><div class="contribution"><div class="authors u-font-sans">D. Dai, Y. Wang, H. Jin, Y. Mao, H. Sun</div><div id="ref-id-sbref0021" class="title text-m">The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis</div></div><div class="host u-font-sans">Rheumatol Int, 37 (7) (2017), pp. 1083-1088</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1007/s00296-017-3704-7" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0021"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85016482118&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0021"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=The%20efficacy%20of%20mycophenolate%20mofetil%20in%20treating%20Takayasu%20arteritis%3A%20a%20systematic%20review%20and%20meta-analysis&amp;publication_year=2017&amp;author=D.%20Dai&amp;author=Y.%20Wang&amp;author=H.%20Jin&amp;author=Y.%20Mao&amp;author=H.%20Sun" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0021"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0022" id="ref-id-bib0022" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[22]</span></span></a></span><span class="reference" id="sbref0022"><div class="contribution"><div class="authors u-font-sans">C. Wu, Y. Sun, X. Cui, S. Wu, L. Ma, H. Chen, <em> et al.</em></div><div id="ref-id-sbref0022" class="title text-m">Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis</div></div><div class="host u-font-sans">Ther Adv Chronic Dis, 11 (2020)</div><div class="comment">2040622320975233</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Effectiveness%20and%20safety%20of%20methotrexate%20versus%20leflunomide%20in%2012-month%20treatment%20for%20Takayasu%20arteritis&amp;publication_year=2020&amp;author=C.%20Wu&amp;author=Y.%20Sun&amp;author=X.%20Cui&amp;author=S.%20Wu&amp;author=L.%20Ma&amp;author=H.%20Chen" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0022"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0023" id="ref-id-bib0023" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[23]</span></span></a></span><span class="reference" id="sbref0023"><div class="contribution"><div class="authors u-font-sans">S. Padiyar, D. Danda, R. Goel, E. Joseph, A.M. Nair, G. Joseph, <em> et al.</em></div><div id="ref-id-sbref0023" class="title text-m">Clinical and angiographic outcomes of mycophenolate versus methotrexate in South Asian patients of Takayasu arteritis: results from an open-label, outcome-assessor blinded randomized controlled trial</div></div><div class="host u-font-sans">Mod Rheumatol, 34 (1) (2023), pp. 175-181</div><div class="ReferenceLinks u-font-sans"><span class="link lazy-third-party-pdf-link"><span></span></span><a class="anchor link anchor-primary" href="https://doi.org/10.1093/mr/roac157" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0023"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Clinical%20and%20angiographic%20outcomes%20of%20mycophenolate%20versus%20methotrexate%20in%20South%20Asian%20patients%20of%20Takayasu%20arteritis%3A%20results%20from%20an%20open-label%2C%20outcome-assessor%20blinded%20randomized%20controlled%20trial&amp;publication_year=2023&amp;author=S.%20Padiyar&amp;author=D.%20Danda&amp;author=R.%20Goel&amp;author=E.%20Joseph&amp;author=A.M.%20Nair&amp;author=G.%20Joseph" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0023"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0024" id="ref-id-bib0024" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[24]</span></span></a></span><span class="reference" id="sbref0024"><div class="contribution"><div class="authors u-font-sans">Y. Nakaoka, M. Isobe, S. Takei, Y. Tanaka, T. Ishii, S. Yokota, <em> et al.</em></div><div id="ref-id-sbref0024" class="title text-m">Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)</div></div><div class="host u-font-sans">Ann Rheum Dis, 77 (3) (2018), pp. 348-354</div><div class="ReferenceLinks u-font-sans"><a class="anchor pdf link anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0003496724009609/pdfft?md5=78caad7e7c2c9a158235176f38e50987&amp;pid=1-s2.0-S0003496724009609-main.pdf" target="_blank" rel="nofollow" aria-describedby="ref-id-sbref0024"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a><a class="anchor link anchor-primary" href="/science/article/pii/S0003496724009609" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">View article</span></span></a><a class="anchor link anchor-primary" href="https://doi.org/10.1136/annrheumdis-2017-211878" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">Crossref</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://www.scopus.com/inward/record.url?eid=2-s2.0-85047261808&amp;partnerID=10&amp;rel=R3.0.0" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">View in Scopus</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20tocilizumab%20in%20patients%20with%20refractory%20Takayasu%20arteritis%3A%20results%20from%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial%20in%20Japan%20&amp;publication_year=2018&amp;author=Y.%20Nakaoka&amp;author=M.%20Isobe&amp;author=S.%20Takei&amp;author=Y.%20Tanaka&amp;author=T.%20Ishii&amp;author=S.%20Yokota" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0024"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li><li><span class="label u-font-sans"><a class="anchor anchor-primary" href="#bbib0025" id="ref-id-bib0025" data-aa-button="sd:product:journal:article:location=references:type=anchor:name=citation-name"><span class="anchor-text-container"><span class="anchor-text">[25]</span></span></a></span><span class="reference" id="sbref0025"><div class="contribution"><div class="authors u-font-sans">Y. Sun, B. Wu, W. Zhang, L. Ma, X. Kong, H. Chen, <em> et al.</em></div><div id="ref-id-sbref0025" class="title text-m">Comparison of the efficacy and safety of leflunomide versus placebo combined with basic prednisone therapy in patients with active disease phase of Takayasu arteritis: study protocol for a randomized, double-blinded controlled trial (Takayasu arteritis clinical trial in China: TACTIC)</div></div><div class="host u-font-sans">Ther Adv Chronic Dis, 14 (2023)</div><div class="comment">20406223231158567</div><div class="ReferenceLinks u-font-sans"><a class="anchor link anchor-primary" href="https://scholar.google.com/scholar_lookup?title=Comparison%20of%20the%20efficacy%20and%20safety%20of%20leflunomide%20versus%20placebo%20combined%20with%20basic%20prednisone%20therapy%20in%20patients%20with%20active%20disease%20phase%20of%20Takayasu%20arteritis%3A%20study%20protocol%20for%20a%20randomized%2C%20double-blinded%20controlled%20trial%20&amp;publication_year=2023&amp;author=Y.%20Sun&amp;author=B.%20Wu&amp;author=W.%20Zhang&amp;author=L.%20Ma&amp;author=X.%20Kong&amp;author=H.%20Chen" target="_blank" rel="noopener noreferrer" aria-describedby="ref-id-sbref0025"><span class="anchor-text-container"><span class="anchor-text">Google Scholar</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></span></li></ol></section></section></div><div id="section-cited-by"><section aria-label="Cited by" class="ListArticles preview"><div class="PageDivider"></div><header id="citing-articles-header"><h2 class="u-h4 u-margin-l-ver u-font-serif">Cited by (0)</h2></header><div aria-describedby="citing-articles-header"></div></section></div><div class="Footnotes text-xs"><dl class="footnote"><dt class="footnote-label"></dt><dd class="footnote-detail u-padding-xs-top"><div class="u-margin-s-bottom" id="notep0001">Xiaochuan Sun and Jing Li contributed equally to this study.</div></dd></dl><dl class="footnote"><dt class="footnote-label"></dt><dd class="footnote-detail u-padding-xs-top"><div class="u-margin-s-bottom" id="notep0002"><strong>Handling editor</strong> Josef S. Smolen.</div></dd></dl></div><div class="Copyright"><span class="copyright-line">© 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).</span></div></article><div class="u-display-block-from-md col-lg-6 col-md-8 pad-right u-padding-s-top"><aside class="RelatedContent u-clr-grey8" aria-label="Related content"><section class="RelatedContentPanel u-margin-s-bottom"><header id="recommended-articles-header" class="related-content-panel-header u-margin-s-bottom"><button class="button-link button-link-secondary related-content-panel-toggle is-up button-link-icon-right button-link-has-colored-icon" type="button" aria-expanded="true" data-aa-button="sd:product:journal:article:location=recommended-articles:type=close"><span class="button-link-text-container"><span class="button-link-text"><h2 class="section-title u-h4"><span class="related-content-panel-title-text">Recommended articles</span></h2></span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></header><div class="" aria-hidden="false" aria-describedby="recommended-articles-header"><div id="recommended-articles" class="text-xs"><ul><li class="RelatedContentPanelItem u-display-block"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article0-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0006497121012465" title="Autoimmune cytopenia and CLL ride together"><span class="anchor-text-container"><span class="anchor-text"><span>Autoimmune cytopenia and CLL ride together</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Blood, Volume 137, Issue 25, 2021, pp. 3464-3465</div></div><div class="authors"><span>Carol</span> <span>Moreno</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S0006497121012465/pdfft?md5=d49437df9e1aa9c8842cccc4c1d5e674&amp;pid=1-s2.0-S0006497121012465-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article0-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-block"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article1-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S1600613525029296" title="Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation"><span class="anchor-text-container"><span class="anchor-text"><span>Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">American Journal of Transplantation, 2025</div></div><div class="authors"><span>Enrico</span> <span>Sanna</span>, …, <span>Luigi</span> <span>Biancone</span></div></div><div class="buttons"><a class="anchor anchor-primary anchor-icon-left anchor-with-icon" href="/science/article/pii/S1600613525029296/pdfft?md5=72aa01018817c9c4740523b05a8187ab&amp;pid=1-s2.0-S1600613525029296-main.pdf" target="_blank" rel="nofollow" aria-describedby="recommended-articles-article1-title"><svg focusable="false" viewBox="0 0 35 32" height="20" class="icon icon-pdf-multicolor"><path d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492
    1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0
    .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0
    1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0
    2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534
    2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317
    2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32
    24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153
    1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306
    2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047
    1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="anchor-text-container"><span class="anchor-text">View PDF</span></span></a></div></li><li class="RelatedContentPanelItem u-display-block"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article2-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0003496725042451" title="The shared debt of art and rheumatology"><span class="anchor-text-container"><span class="anchor-text"><span>The shared debt of art and rheumatology</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, 2025</div></div><div class="authors"><span>Alain</span> <span>Saraux</span>, …, <span>Dominique</span> <span>Le Nen</span></div></div><div class="buttons"></div></li><li class="RelatedContentPanelItem u-display-none"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article3-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0003496725042438" title="Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis"><span class="anchor-text-container"><span class="anchor-text"><span>Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Annals of the Rheumatic Diseases, Volume 84, Issue 10, 2025, pp. 1632-1640</div></div><div class="authors"><span>Andreas</span> <span>Kerschbaumer</span>, …, <span>Daniel</span> <span>Aletaha</span></div></div><div class="buttons"></div></li><li class="RelatedContentPanelItem u-display-none"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article4-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S0049017225001854" title="Concordance of relapse symptoms in patients with giant cell arteritis"><span class="anchor-text-container"><span class="anchor-text"><span>Concordance of relapse symptoms in patients with giant cell arteritis</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">Seminars in Arthritis and Rheumatism, Volume 74, 2025, Article 152814</div></div><div class="authors"><span>Max</span> <span>Guarda</span>, …, <span>Matthew J.</span> <span>Koster</span></div></div><div class="buttons"></div></li><li class="RelatedContentPanelItem u-display-none"><div class="sub-heading u-padding-xs-bottom"><h3 class="related-content-panel-list-entry-outline-padding text-s u-font-serif" id="recommended-articles-article5-title"><a class="anchor u-clamp-2-lines anchor-primary" href="/science/article/pii/S2665991325000700" title="Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial"><span class="anchor-text-container"><span class="anchor-text"><span>Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial</span></span></span></a></h3><div class="article-source u-clr-grey6"><div class="source">The Lancet Rheumatology, Volume 7, Issue 9, 2025, pp. e642-e651</div></div><div class="authors"><span>Amy C D</span> <span>Peeters</span>, …, <span>Noortje</span> <span>van Herwaarden</span></div></div><div class="buttons"></div></li></ul></div><button class="button-link more-recommendations-button u-margin-s-bottom button-link-primary button-link-icon-right" type="button"><span class="button-link-text-container"><span class="button-link-text">Show 3 more articles</span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></div></section><section class="RelatedContentPanel u-margin-s-bottom"><header id="metrics-header" class="related-content-panel-header u-margin-s-bottom"><button class="button-link button-link-secondary related-content-panel-toggle is-up button-link-icon-right button-link-has-colored-icon" type="button" aria-expanded="true"><span class="button-link-text-container"><span class="button-link-text"><h2 class="section-title u-h4"><span class="related-content-panel-title-text">Article Metrics</span></h2></span></span><svg focusable="false" viewBox="0 0 92 128" height="20" class="icon icon-navigate-down"><path d="M1 51l7-7 38 38 38-38 7 7-45 45z"></path></svg></button></header><div class="" aria-hidden="false" aria-describedby="metrics-header"><div class="plumX-metrics"><h3 class="text-s metric-title metric-title-captures">Captures</h3><ul><li class="text-xs metrics"><span>Mendeley Readers</span><span>4</span></li></ul><h3 class="text-s metric-title metric-title-mentions">Mentions</h3><ul><li class="text-xs metrics"><span>News Mentions</span><span>1</span></li></ul><div class="metrics u-margin-m-top u-margin-s-bottom"><img src="https://cdn.plu.mx/3ba727faf225e19d2c759f6ebffc511d/plumx-logo.png" class="plumX-logo" alt="PlumX Metrics Logo"><a class="anchor text-xs anchor-primary" href="https://plu.mx/plum/a/?doi=10.1016%2Fj.ard.2025.07.018&amp;theme=plum-sciencedirect-theme&amp;hideUsage=true" target="_blank"><span class="anchor-text-container"><span class="anchor-text">View details</span><svg focusable="false" viewBox="0 0 8 8" height="20" aria-label="Opens in new window" class="icon icon-arrow-up-right-tiny arrow-external-link"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span></a></div></div></div></section></aside></div></div></div>